Biodelivery Sciences International (BDSI) 10-K 14 Mar 19 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2018	Mar. 14, 2019	Jun. 29, 2018
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Trading Symbol	BDSI
Entity Registrant Name	BIODELIVERY SCIENCES INTERNATIONAL INC
Entity Central Index Key	0001103021
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Small Business	false
EntityShellCompany	false
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		70,952,944
Entity Public Float			$ 113,670,574

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash	$ 43,822	$ 21,195
Accounts receivable, net	13,627	8,852
Inventory, net	5,406	6,091
Prepaid expenses and other current assets	3,188	3,610
Total current assets	66,043	39,748
Property and equipment, net	3,072	3,778
Goodwill	2,715	2,715
BELBUCA license and distribution rights, net	36,000	40,500
Other intangible assets, net	703	1,360
Total assets	108,533	88,101
Current liabilities:
Accounts payable and accrued liabilities	21,539	26,149
Total current liabilities	21,539	26,149
Notes payable, net	51,652	47,660
Other long-term liabilities	5,600	5,415
Total liabilities	78,791	79,224
Commitments and contingencies (Notes 7 and 17)
Stockholders' equity:
Preferred Stock	2	2
Common Stock, $.001 par value; 125,000,000 and 75,000,000 shares authorized at December 31, 2018 and December 31, 2017, respectively; 70,793,725 and 55,904,072 shares issued; 70,778,234 and 55,888,581 shares outstanding at September 30, 2018 and December 31, 2017, respectively.	71	56
Additional paid-in capital	381,004	313,922
Treasury stock, at cost, 15,491 shares	(47)	(47)
Accumulated deficit	(351,288)	(305,056)
Total stockholders' equity	29,742	8,877
Total liabilities and stockholders' equity	$ 108,533	$ 88,101

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Preferred Stock, par value	$ 0.001
Preferred Stock, shares authorized	5,000,000
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, shares authorized	125,000,000	75,000,000
Common Stock, shares issued	70,793,725	55,904,072
Common Stock, shares outstanding	70,778,234	55,888,581
Treasury stock, shares	15,491	15,491
Series A Non-Voting Convertible Preferred Stock [Member]
Preferred Stock, par value	$ 0.001	$ 0.001
Preferred Stock, shares authorized	5,000,000	5,000,000
Preferred Stock, shares outstanding	2,093,155	2,093,155
Series B Non-Voting Convertible Preferred Stock [Member]
Preferred Stock, par value	$ 0.001	$ 0.001
Preferred Stock, shares authorized	5,000,000	5,000,000
Preferred Stock, shares outstanding	3,100	0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Revenues:
Total revenues	$ 55,640	$ 61,985	$ 15,546
Cost of sales	15,783	19,496	11,258
Expenses:
Research and development	4,903	13,040	18,878
Selling, general and administrative	58,602	58,869	49,345
Total expenses	63,505	71,909	68,223
Loss from operations	(23,648)	(29,420)	(63,935)
Interest expense	(10,192)	(8,577)	(3,267)
Bargain purchase gain		27,336
Other (expense) income, net	(14)	(26)	64
Loss before income taxes	(33,854)	(10,687)	(67,138)
Income tax benefit	(13)	15,972
Net (loss) income	(33,867)	5,285	(67,138)
Beneficial conversion feature of convertible preferred stock	(12,500)
Net (loss) income attributable to common stockholders	$ (46,367)	$ 5,285	$ (67,138)
Basic:
Weighted average common stock shares outstanding	63,165,063	55,355,802	53,679,134
Basic (loss) earnings per share	$ (0.73)	$ 0.10	$ (1.25)
Diluted:
Diluted weighted average common stock shares outstanding	63,165,063	56,402,479	53,679,134
Diluted (loss) earnings per share	$ (0.73)	$ 0.09	$ (1.25)
Product Sales [Member]
Revenues:
Total revenues	$ 51,410	$ 34,922	$ 8,266
Product Royalty Revenues [Member]
Revenues:
Total revenues	3,389	5,070	3,646
Research And Development Reimbursements [Member]
Revenues:
Total revenues		799	1,134
Contract Revenues [Member]
Revenues:
Total revenues	$ 841	$ 21,194	$ 2,500

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Treasury Stock [Member]	Accumulated Deficit [Member]	Series A Preferred Stock [Member]	Series B Preferred Stock [Member]
Beginning Balance at Dec. 31, 2015	$ 31,696	$ 53	$ 274,891	$ (47)	$ (243,203)	$ 2
Beginning Balance, shares at Dec. 31, 2015		52,730,799				2,093,155
Stock-based compensation	$ 14,931		$ 14,931
Stock-based compensation, Shares	0	0	0	0	0	0	0
Stock option exercises	$ 297		$ 297
Stock option exercises, shares	147,425	147,426
Restricted stock awards, shares		592,065
Common stock issuance upon retirement	$ 2,460	$ 1	2,459
Common stock issuance upon retirement, shares		663,221
Issuance of warrants	49		49
Equity finance costs	40		40
Net income (loss)	(67,138)				$ (67,138)
Ending Balance at Dec. 31, 2016	(17,665)	$ 54	292,667	$ (47)	$ (310,341)	$ 2
Ending Balance, shares at Dec. 31, 2016		54,133,511				2,093,155
Stock-based compensation	$ 14,801		$ 14,801
Stock-based compensation, Shares	0	0	0	0	0	0	0
Stock option exercises	$ 439		$ 439
Stock option exercises, shares	202,519	202,519
Restricted stock awards		$ 2	(2)
Restricted stock awards, shares		1,568,042
Issuance of warrants	$ 6,017		6,017
Net income (loss)	5,285				$ 5,285
Ending Balance at Dec. 31, 2017	8,877	$ 56	313,922	$ (47)	$ (305,056)	$ 2
Ending Balance, shares at Dec. 31, 2017		55,904,072				2,093,155
Stock-based compensation	$ 5,941		$ 5,941
Stock-based compensation, Shares	0	0	0	0	0	0	0
Stock option exercises	$ 670		$ 670
Stock option exercises, shares	350,441	350,441
Restricted stock awards		$ 2	(2)
Restricted stock awards, shares		1,733,731
Common stock issuance upon retirement		$ 2	(2)
Common stock issuance upon retirement, shares	2,119,925	2,249,925
Series B issuance, net of issuance costs	$ 47,986		47,986
Series B issuance, net of issuance costs, shares							5,000
Series B conversion to Common Stock		$ 11	(11)
Series B conversion to Common Stock, shares		10,555,556					(1,900)
Series B beneficial conversion feature	(12,500)		12,500		$ (12,500)
Cumulative effect of accounting change	135				135
Net income (loss)	(33,867)				(33,867)
Ending Balance at Dec. 31, 2018	$ 29,742	$ 71	$ 381,004	$ (47)	$ (351,288)	$ 2
Ending Balance, shares at Dec. 31, 2018		70,793,725				2,093,155	3,100

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Operating activities:
Net (loss) income	$ (33,867)	$ 5,285	$ (67,138)
Adjustments to reconcile net (loss) income to net cash flows used in operating activities
Depreciation	740	693	437
Accretion of debt discount and loan costs	4,138	2,392	397
Amortization of intangible assets	5,157	5,425	971
(Recovery from) provision for inventory obsolescence	(56)	243
Impairment loss on equipment	78
Stock-based compensation expense	5,941	14,801	14,931
Deferred income taxes	40	(15,972)
Bargain purchase gain		(27,336)
Changes in assets and liabilities, net of effect of acquisition:
Accounts receivable	(4,640)	(5,884)	(862)
Inventories	741	2,448	(810)
Prepaid expenses and other assets	422	526	(203)
Accounts payable and accrued expenses	(2,807)	6,644	(1,546)
Deferred revenue		(21,716)	(159)
Net cash flows used in operating activities	(24,113)	(32,451)	(53,982)
Investing activities:
BELBUCA acquisition	(1,951)	(5,853)
Purchase of equipment	(112)	(11)	(405)
Net cash flows used in investing activities	(2,063)	(5,864)	(405)
Financing activities:
Proceeds from sales of securities, net of costs incurred			40
Proceeds from exercise of stock options	670	439	297
Issuance of common stock			2,460
Issuance of warrants			49
Proceeds from issuance of Series B preferred stock	50,000
Payment on note payable		(30,000)
Proceeds from notes payable		60,000
Equity finance costs	(1,417)
Payment of deferred financing fees	(450)	(2,948)
Net cash flows from financing activities	48,803	27,491	2,846
Net change in cash and cash equivalents	22,627	(10,824)	(51,541)
Cash and cash equivalents at beginning of year	21,195	32,019	83,560
Cash and cash equivalents at end of year	43,822	21,195	32,019
Cash paid for interest	6,053	5,285	$ 2,870
Non-cash Financing and Investing Activities:
Adjustments to additional paid in capital dividends in excess of retained earnings	$ 12,500
Common stock issuance upon retirement, shares	2,119,925
Common stock issuance upon retirement	$ 5,300
Fair value of bargain purchase price of BELBUCA acquisition		27,300
Fair value of warrants, in connection with CRG term loan		$ 6,000
Series B Non-Voting Convertible Preferred Stock [Member]
Non-cash Financing and Investing Activities:
Adjustments to additional paid in capital dividends in excess of retained earnings	12,500
Accrued financing expenses	$ 600

Nature of Business and Summary

Nature of Business and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Nature of Business and Summary of Significant Accounting Policies	1. Nature of business and summary of significant accounting policies: Organization BioDelivery Sciences International, Inc. and subsidiaries (the “Company”) was incorporated in the State of Indiana on January 6, 1997 and reincorporated as a Delaware corporation in 2002. The Company’s subsidiaries are Arius Pharmaceuticals, Inc., a Delaware corporation (“Arius One”) and Arius Two, Inc., a Delaware corporation (“Arius Two”), each of which are wholly-owned, and its majority-owned subsidiary, Bioral Nutrient Delivery, LLC, a Delaware limited liability company (“BND”). The Company is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain. The Company has built a portfolio of products utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA ® The Company’s historical clinical and regulatory development strategy has focused primarily on its ability to use the U.S. Food and Drug Administration’s (“FDA’s”) 505(b)(2) approval process to obtain more timely and efficient approval of new formulations of previously approved, active therapeutics incorporated into the Company’s drug-delivery technology. As used herein, the Company’s common stock, par value $.001 per share, is referred to as the “Common Stock” and the Company’s preferred stock, par value $0.001 per share, is referred to as the “Preferred Stock”. Principles of consolidation The consolidated financial statements include the accounts of the Company, Arius One, Arius Two and BND. For each period presented BND has been an inactive subsidiary. All significant inter-company balances and transactions have been eliminated. Significant accounting policies: Use of estimates in financial statements The preparation of the accompanying consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. The Company reviews all significant estimates affecting the consolidated financial statements on a recurring basis and records the effect of any necessary adjustments prior to their issuance. Significant estimates of the Company include: revenue recognition, sales allowances such as returns of product sold, government program rebates, customer coupon redemptions, wholesaler/pharmacy discounts, product service fees, rebates and chargebacks, sales bonuses, stock-based compensation, determination of fair values of assets and liabilities relating to business combinations, and deferred income taxes. Certain risks, concentrations and uncertainties The Company relies on certain materials used in its development and third-party manufacturing processes, most of which are procured from three contract manufacturers and two active pharmaceutical ingredient (“API”) suppliers for BELBUCA and BUNAVAIL ® In addition, the Company utilizes only two contract manufacturers to create the BELBUCA and BUNAVAIL laminates and only one contract manufacturer to package the laminates into final product. Although the Company has long term supply agreements with these two vendors, any problems or regulatory issues at either of these vendors could create significant BELBUCA and BUNAVAIL supply delays. Amounts due to these vendors represented approximately 6.3% and 22.8% of total accounts payable as of December 31, 2018 and 2017, respectively. Key components used in the manufacture of ONSOLIS ® The Company sells its BELBUCA and BUNAVAIL products primarily to large national wholesalers, which in turn may resell the products to smaller or regional wholesalers, retail pharmacies, chain drug stores, government agencies and other third parties. The following table lists the Company’s customers that individually comprise greater than 10% of total accounts receivable: December 31, Customers 2018 2017 Customer A 47 % 47 % Customer B 22 % 22 % Customer C 25 % 26 % Total 94 % 95 % These three customers accounted for 92%, 92% and 91% of total annual sales during the years ended December 31, 2018, 2017 and 2016 respectively. Cash The Company places cash on deposit with financial institutions in the United States. The Federal Deposit Insurance Corporation covers $0.25 million for substantially all depository accounts. As of December 31, 2018, the Company had approximately $43.6 million, which exceeded these insured limits. As of December 31, 2017, the Company had approximately $21.2 million, which exceeded these insured limits. Accounts receivable The Company typically requires its customers to remit payments within the first 30 to 37 days, depending on the customer and the products purchased and agreed upon terms. In addition, the Company offers wholesale distributors a prompt payment discount if they make payments within these deadlines. This discount is generally 2% but may be higher in some instances due to product launches or customer and/or industry expectations. Because the Company’s wholesale distributors typically take the prompt payment discount, the Company accrues 100% of the prompt payment discounts, based on the gross amount of each invoice, at the time of sale, and the Company applies earned discounts at the time of payment. The allowance for prompt payment discounts was $0.3 million and $0.2 million as of December 31, 2018 and 2017, respectively. The Company performs ongoing credit evaluations and does not require collateral. As appropriate, the Company establishes provisions for potential credit losses. There were no allowances for doubtful accounts as of December 31, 2018 or 2017. The Company writes off accounts receivable when management determines they are uncollectible and credits payments subsequently received on such receivables to bad debt expense in the period received. Inventory Inventories are stated at the lower of cost or net realizable value with costs determined for each batch under the first-in, first-out On a quarterly basis, the Company analyzes its inventory levels and records allowances for inventory that has become obsolete, inventory that has a cost basis more than the expected net realizable value and inventory that is more than expected demand based upon projected product sales. The Company recorded a $0.2 million in reserve for inventory obsolescence as of December 31, 2018, and 2017. Inventory is composed of the following at December 31: 2018 2017 Raw Materials & Supplies $ 645 $ 1,338 Work-in-process 2,093 3,135 Finished Goods 2,855 1,861 Finished Goods Reserve (187 ) (243 ) Total Inventories $ 5,406 $ 6,091 Property and equipment The Company records property and equipment at cost less accumulated depreciation, which is computed on a straight-line basis over its estimated useful lives, generally 3 to 10 years. The Company evaluates the carrying value of equipment when events or changes in circumstances indicate the related carrying amount may not be recoverable. The Company has certain manufacturing equipment that isn’t currently in production, which has been deemed idle. There was no impairment of equipment recorded during the year ended December 31, 2018 or 2017. Intangibles and goodwill The Company reviews intangible assets with finite lives (“other intangible assets”) for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company uses an estimate of the undiscounted cash flows over the remaining life of its other intangible assets, or related group of assets where applicable, in measuring whether the assets to be held and used will be realizable. In the event of impairment, the Company would discount the future cash flows using its then estimated incremental borrowing rate to estimate the amount of the impairment. There were no impairment charges recognized on finite lived intangibles in 2018, 2017 or 2016. Intangible assets with finite useful lives are amortized over the estimated useful lives as follows: Estimated Licenses 15 years BELBUCA license and distribution rights 10 years U.S. product rights 8-12 years EU product rights 7-11 Goodwill is evaluated for impairment at least annually or more frequently if events or changes in circumstances indicate that the carrying amount may not be recoverable. During the evaluation of the potential impairment of goodwill, either a qualitative or a quantitative assessment may be performed. If a qualitative evaluation determines that it is more likely than not that no impairment exists, then no further analysis is performed. If a qualitative evaluation is unable to determine whether it is more likely than not that impairment has occurred, a quantitative evaluation is performed. If the carrying value exceeds the fair value, an impairment charge is recorded based on that difference. There were no goodwill impairment charges in 2018, 2017 or 2016. Revenue recognition Product sales As discussed further below in Note 2, effective January 1, 2018, the Company adopted Accounting Standards Update (“ASU”) 2014-09, Performance obligations A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in Topic 606. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The majority of the Company’s product sales contracts have a single performance obligation as the promise to transfer the individual goods is not separately identifiable from other promises in the contracts and, therefore, not distinct. The Company’s performance obligations are satisfied at a point in time. The multiple performance obligations are not allocated based off of the obligations but based off of standard selling price. Adjustments to product sales The Company recognizes product sales net of estimated allowances for rebates, price adjustments, returns, chargebacks and prompt payment discounts. A significant majority of the Company’s adjustments to gross product revenues are the result of accruals for its commercial contracts, retail consumer subsidy programs, and Medicaid rebates. The Company establishes allowances for estimated rebates, chargebacks and product returns based on numerous qualitative and quantitative factors, including: • the number of and specific contractual terms of agreements with customers; • estimated levels of inventory in the distribution channel; • historical rebates, chargebacks and returns of products; • direct communication with customers; • anticipated introduction of competitive products or generics; • anticipated pricing strategy changes by the Company and/or its competitors; • analysis of prescription data gathered by a third-party prescription data provider; • the impact of changes in state and federal regulations; and • the estimated remaining shelf life of products. In its analyses, the Company uses prescription data purchased from a third-party data provider to develop estimates of historical inventory channel sell-through. The Company utilizes an internal analysis to compare historical net product shipments to estimated historical prescriptions written. Based on that analysis, management develops an estimate of the quantity of product in the channel which may be subject to various rebate, chargeback and product return exposures. To estimate months of ending inventory in the Company’s distribution channel, the Company divides estimated ending inventory in the distribution channel by the Company’s recent prescription data, not considering any future anticipated demand growth beyond the succeeding quarter. Monthly for each product line, the Company prepares an internal estimate of ending inventory units in the distribution channel by adding estimated inventory in the channel at the beginning of the period, plus net product shipments for the period, less estimated prescriptions written for the period. This is done for each product line by applying a rate of historical activity for rebates, chargebacks and product returns, adjusted for relevant quantitative and qualitative factors discussed above, to the potential exposed product estimated to be in the distribution channel. In addition, the Company receives daily information from the wholesalers regarding their sales and actual on hand inventory levels of the Company’s products. This enables the Company to execute accurate provisioning procedures. Product returns 18-month Rebates Price adjustments and chargebacks The Company, from time to time, offers certain promotional product-related incentives to its customers. These programs include certain product incentives to pharmacy customers and other sales stocking allowances. The Company has voucher programs for BELBUCA and BUNAVAIL whereby the Company offers a point-of-sale Prompt payment discounts Gross to net accruals License and development agreements The Company periodically enters into license and development agreements to develop and commercialize its products. The arrangements typically are multi-deliverable arrangements that are funded through upfront payments, milestone payments and other forms of payment. The Company currently has multiple license and development agreements that are described in notes 7, 9 and 10. Depending on the nature of the contract these revenues are classified as research and development reimbursements or contract revenue. Cost of sales Cost of sales includes the direct costs attributable to the production of BELBUCA and BUNAVAIL. It includes raw materials, production costs at the Company’s three contract manufacturing sites, quality testing directly related to the products, and depreciation on equipment that the Company has purchased to produce BELBUCA and BUNAVAIL. It also includes any batches not meeting specifications and raw material yield losses. Yield losses and batches not meeting specifications are expensed as incurred. Cost of sales is recognized when sold to the wholesaler from our distribution center. For BREAKYL and PAINKYL (the Company’s out-licensed Research and development expenses Research and development expenses have historically consisted of product development expenses incurred in identifying, developing and testing product candidates. Product development expenses consist primarily of labor, benefits and related employee expenses for personnel directly involved in product development activities; fees paid to professional service providers for monitoring and analyzing clinical trials; regulatory costs; costs of contract research and manufacturing of inventory used in testing and clinical trials. Product development expenses are expensed as incurred and reflect costs directly attributable to product candidates in development during the applicable period and to product candidates for which the Company has discontinued development. All indirect costs (such as salaries, benefits or other costs related to the Company’s accounting, legal, human resources, purchasing, information technology and other general corporate functions) associated with individual product candidates are included in general and administrative expenses. Advertising Advertising costs, which include promotional expenses and the cost of placebo samples, are expensed as incurred. Advertising expenses were $4.5 million, $3.8 million and $4.2 million for the years ended December 31, 2018, 2017 and 2016, respectively, and are included in selling, general and administrative expenses in the accompanying consolidated statements of operations. Shipping and handling costs Shipping and handling costs, which include expenses from our wholesalers, are expensed as incurred. Shipping and handling costs were $0.02 million, $0.01 and $0.01 million for the years ended December 31, 2018, 2017 and 2016, respectively, and are included in selling, general and administrative expenses in the accompanying consolidated statements of operations. Stock-based compensation The Company has a stock-based compensation plan under which various types of equity-based awards are granted, including stock options, restricted stock units (RSUs) and performance-based RSUs. The fair value of stock option and RSUs, which are subject only to service conditions with graded vesting, are recognized as compensation expense, generally on a straight-line basis over the service period, net of estimated forfeitures. Forfeitures are recognized as they occur. The fair values of performance-based RSUs are recognized as compensation expense from the grant date to the end of the performance period. The Company uses the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (warrants and options). The grant date fair value of an RSU equals the closing price of our common stock on the trading day preceding the grant date. The fair value of each option and warrant is estimated on the date of grant using the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate. Expected volatility is based on historical volatility of the Company’s Common Stock and other factors estimated over the expected term of the options. The expected term of options granted is derived using the “simplified method” which computes expected term as the average of the sum of the vesting term plus the contract term. The risk-free rate is based on the U.S. Treasury yield. In applying the Black-Scholes options-pricing model, assumptions are as follows: 2018 2017 2016 Expected price volatility 60.34%-68.77% 68.76%-78.79% 62.65%-80.78% Risk-free interest rate 2.05%-3.00% 1.77%-2.05% 0.56%-1.70% Weighted average expected life in years 6 years 6 years 6 years Dividend yield — — — Fair Value of Financial Instruments The Company measures the fair value of instruments in accordance with GAAP which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. GAAP also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. GAAP describes three levels of inputs that may be used to measure fair value: Level 1 – quoted prices in active markets for identical assets or liabilities Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions) Recent accounting pronouncements-adopted The SEC has released SEC Final Rule Release No. 33-10532 In the first quarter of 2018, the Company adopted Topic 606. Under the standard, revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration the entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The Company applied the five-step method outlined in the ASU to all revenue streams and elected the modified retrospective implementation method. The additional disclosures required by Topic 606 have been included in Note 2. Recent accounting pronouncements-issued, not yet adopted In November 2018, the FASB issued ASU “Collaborative Arrangements (Topic 808) – Clarifying the Interaction between Topic 808 and Topic 606” (“ASU 2018-18”). 2018-18 make unit-of-account 2018-18 is ASU 2016-02, However, unlike current GAAP which requires only capital leases to be recognized on the balance sheet, the new ASU will require both types of leases (i.e., operating and finance leases) to be recognized on the balance sheet. The FASB lessee accounting model will continue to account for both types of leases. The finance lease will be accounted for in substantially the same manner as capital leases are accounted for under existing GAAP. The operating lease will be accounted for in a manner similar to operating leases under existing GAAP, except that lessees will recognize a lease liability and a right-of-use The Company will adopt and implement this standard on January 1, 2019, using the required modified-retrospective approach as of the effective date. The Company will elect the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allows us to carryforward the historical lease classification. The Company will make an accounting policy election to account for leases with an initial term of 12 months or less similar to existing guidance for operating leases today. The Company will recognize those lease payments in the Consolidated Statements of Operations on a straight-line basis over the lease term. The Company is substantially complete with its implementation to the new leasing standard and believes that the transition will not have a material impact on its consolidated balance sheet. As disclosed in Note 18 – Commitments and Contingencies, the Company has approximately $1.3 million in future minimum lease commitments as of the year ended December 31, 2018. Upon adoption, the Company’s lease liability will generally be based on the present value of such payments and the related right-of-use The Company has estimated the right-of-use

Revenue from Contracts with Cus

Revenue from Contracts with Customers	12 Months Ended
	Dec. 31, 2018
Revenue from Contract with Customer [Abstract]
Revenue from Contracts with Customers	2. Revenue from contracts with customers: Effective January 1, 2018, the Company adopted Topic 606. The Company elected to apply the standard using the modified retrospective method beginning January 1, 2018. The Company applied this guidance only to those contracts that were not completed at the date of adoption. As a result of adoption, the cumulative impact to the Company’s retained earnings at January 1, 2018 was $0.135 million. The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods. There were no significant changes in the timing or amount of revenue recognized for the Company’s product sales and related gross-to-net gross-to-net Under the new standard, timing for recognition of certain contract revenue may be accelerated such that a portion of revenue will be estimated and recognized in revenue earlier than the previous accounting standards. During the year ended December 31, 2018, the Company recorded financing revenue for a milestone that is not due until 2020. The main types of revenue contracts are: • Product sales- • Product royalty revenues- ™ ™ • Contract revenue- The impact of adoption of Topic 606 on the Company’s consolidated balance sheet as of December 31, 2018 follows (in thousands): Consolidated Balance Sheet December 31, 2018 As reported Balances Effect of Accounts receivable, net $ 13,627 $ 13,462 $ 165 Accumulated deficit $ (351,288 ) $ (351,453 ) $ 165 The impact of adoption of Topic 606 on the Company’s consolidated statement of operations for the year ended December 31, 2018 follows (in thousands): Consolidated As Balances Effect of Product sales $ 51,410 $ 51,410 $ — Product royalty revenues 3,389 3,389 — Contract revenues 841 811 30 Total revenues $ 55,640 $ 55,610 $ 30 Net loss $ (33,867 ) $ (33,897 ) $ 30 The beginning and ending balances of the Company’s accounts receivables with customers from contracts during the periods presented is as follows (in thousands): Balance at Year Balance at Accounts receivable with customers $ 8,987 $ 4,640 $ 13,627 On January 8, 2019, Purdue terminated their license agreement with the Company which was effective March 11, 2019 (See Note 10, Other license agreements and acquired product rights). Therefore, all previously presented contract revenue for future milestones related to the Purdue agreement as a result of the adoption of Topic 606 during the year ended December 31, 2018 has been reversed. The total amount reversed is $0.2 million and is recorded in the accompanying consolidated statement of operations for the year ended December 31, 2018.

Liquidity

Liquidity	12 Months Ended
	Dec. 31, 2018
Text Block [Abstract]
Liquidity	3. Liquidity: At December 31, 2018, the Company had cash of approximately $43.8 million. The Company used $24.1 million of cash in operations during the year ended December 31, 2018 and had stockholders’ equity of $29.7 million, versus stockholders’ equity of $8.9 million at December 31, 2017. The Company believes that it has sufficient current cash, along with expected proceeds from sales to manage the business as currently planned. The Company’s cash on hand estimation assumes that the Company does not otherwise face unexpected events, costs or contingencies, any of which could affect the Company’s cash requirements from time to time. Available resources may be consumed more rapidly than currently anticipated, potentially resulting in the need for additional funding. Additional funding, capital or loans (including, without limitation, milestone or other payments from commercialization agreements) may be unavailable on favorable terms, if at all, which could leave the Company without adequate capital resources.

Accounts Payable and Accrued Li

Accounts Payable and Accrued Liabilities	12 Months Ended
	Dec. 31, 2018
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities	4. Accounts payable and accrued liabilities: The following table represents the components of accounts payable and accrued liabilities as of December 31: 2018 2017 Accounts payable $ 3,166 $ 12,236 Accrued rebates 12,261 5,648 Accrued compensation and benefits 3,814 3,472 Accrued acquisition costs 318 2,311 Accrued returns 715 915 Accrued royalties 159 488 Accrued clinical trial costs 464 234 Accrued legal 70 216 Accrued other 572 629 Total accounts payable and accrued expenses $ 21,539 $ 26,149 As of December 31, 2018, three vendors comprised 37% of the accounts payable balance. As of December 31, 2017, three vendors comprised 39% of the accounts payable balance.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Property and Equipment	5. Property and equipment: Property and equipment, summarized by major category, consist of the following as of December 31: 2018 2017 Machinery & equipment $ 5,635 $ 5,428 Computer equipment & software 406 399 Office furniture & equipment 155 169 Leasehold improvements 43 44 Idle equipment 679 766 Total 6,918 6,806 Less accumulated depreciation (3,846 ) (3,028 ) Total property, plant & equipment, net $ 3,072 $ 3,778 Depreciation expense for years ended December 31, 2018, 2017 and 2016 was approximately $1.0 million, $0.7 million and $0.4 million, respectively.

Other Intangible Assets

Other Intangible Assets	12 Months Ended
	Dec. 31, 2018
Text Block [Abstract]
Other Intangible Assets	6. Other intangible assets: Other intangible assets, net, consisting of product rights and licenses are summarized as follows: December 31, 2018 Gross Carrying Accumulated Intangible Assets, Weighted average Product rights $ 6,050 $ (5,442 ) $ 608 1.08 BELBUCA license and distribution rights 45,000 (9,000 ) 36,000 7.65 Licenses 1,900 (1,805 ) 95 0.50 Total intangible assets $ 52,950 $ (16,247 ) $ 36,703 9.23 December 31, 2017 Gross Carrying Accumulated Intangible Assets, Weighted average Product rights $ 6,050 $ (4,881 ) $ 1,169 1.21 BELBUCA license and distribution rights 45,000 (4,500 ) 40,500 8.50 Licenses 1,900 (1,709 ) 191 0.54 Total intangible assets $ 52,950 $ (11,090 ) $ 41,860 10.25 The Company incurred amortization expense on other intangible assets of approximately $5.2 million, $5.4 million and $1.0 million for the years ended December 31, 2018, 2017 and 2016, respectively. Estimated aggregate future amortization expenses for other intangible assets for each of the next five years and thereafter are as follows: Years ending December 31, 2019 $ 5,157 2020 4,546 2021 4,500 2022 4,500 2023 4,500 Thereafter 13,500 $ 36,703

License and Development Agreeme

License and Development Agreements	12 Months Ended
	Dec. 31, 2018
Business Combinations [Abstract]
License and Development Agreements	7. License and development agreements: The Company periodically enters into license and development agreements to develop and commercialize its products. The arrangements typically are multi-deliverable arrangements that are funded through upfront payments, milestone payments, royalties and other forms of payment to the Company. The Company’s most significant license and development agreements are as follows: Endo license and development agreement In January 2012, the Company entered into a License and Development Agreement with Endo Pharmaceuticals, Inc. (“Endo”) pursuant to which the Company granted Endo an exclusive commercial world-wide license to develop, manufacture, market and sell the Company’s BELBUCA product and to complete U.S. development of such product candidate for purposes of seeking FDA approval (the “Endo Agreement”). Pursuant to the Endo Agreement, Endo had obtained all rights necessary to complete the clinical and commercial development of BELBUCA and to sell the product worldwide. Pursuant to the Endo Agreement, the Company has received the following payments: • $50 million upon regulatory approval, earned in October 2015 and received in November 2015. Of the $50 million received in November 2015, $20 million related to a patent extension and was recorded as deferred revenue because all or a portion of such $20 million was contingently refundable to Endo if a third party generic product was introduced in the U.S. during the patent extension period from 2020 to 2027. However, due to the Company and Endo entering into a Termination Agreement on December 7, 2016 which terminated the BELBUCA license to Endo effective January 6, 2017, the deferred $20 million was recognized as revenue in January 2017. (See note 8, Business Combinations and BELBUCA Acquisition). Collegium license and development agreement On May 11, 2016, the Company and Collegium executed a License Agreement under which the Company granted Collegium the exclusive rights to develop and commercialize ONSOLIS in the U.S. Under the terms of the License Agreement, Collegium was responsible for the manufacturing, distribution, marketing and sales of ONSOLIS in the U.S. The Company was obligated to use commercially reasonable efforts to continue the transfer of manufacturing to the anticipated manufacturer for ONSOLIS and to submit a corresponding Prior Approval Supplement (the “Supplement”) to the FDA with respect to the current NDA for ONSOLIS. Following approval of the Supplement, the NDA and manufacturing responsibility for ONSOLIS (including the manufacturing relationship with the Company’s manufacturer, subject to the Company entering into an appropriate agreement with such manufacturer that is acceptable and assignable to Collegium) would have been transferred to Collegium. On December 8, 2017, the Company received the required 90-day notice Pursuant to the Collegium Agreement, the Company has received the following payments: • a $2.5 million upfront non-refundable • reimbursement to the Company for a pre-determined

Business Combination and BELBUC

Business Combination and BELBUCA Acquisition	12 Months Ended
	Dec. 31, 2018
Business Combinations [Abstract]
Business Combination and BELBUCA Acquisition	8. Business combination and BELBUCA acquisition: On December 7, 2016, the Company and Endo entered into the Termination Agreement to terminate Endo’s licensing rights for BELBUCA. The transaction closed on January 6, 2017. At the closing date, the Company purchased from Endo the following net assets (the “net assets”): (i) current BELBUCA product inventory and work-in-progress, (v) all pre-approval regulatory At the closing date, the Company accepted transfer of the net assets and assumed and agreed to discharge when due all applicable liabilities assumed by the Company, which consisted of post-closing obligations for liabilities and payments associated with the net assets, the assumed contracts related to the net assets and applicable taxes (with the obligation for pre-closing non-compete The BELBUCA acquisition was accounted for as a business combination in accordance with ASC No. 805, Business Combinations which, among other things, requires assets acquired and liabilities assumed to be measured at their acquisition date fair values. Determining the fair value of certain acquired assets and liabilities is subjective in nature and often involves the use of significant estimates and assumptions, including, but not limited to, the selection of appropriate valuation methodology, projected revenue, expenses and cash flows, weighted average cost of capital, discount rates, and estimates of terminal values. The Company believes the estimates used are reasonable and the significant effects of the BELBUCA acquisition are properly reflected. The following table summarizes the consideration paid to acquire BELBUCA and the estimated values of assets acquired and liabilities assumed in the accompanying consolidated balance sheet based on their fair values on January 6, 2017 (the date of the Endo Closing): Asset purchase price: Deferred cash consideration to Endo $ 7,536 Total asset purchase price $ 7,536 Estimated fair value of assets acquired: BELBUCA product inventory and work-in $ 5,412 BELBUCA-related manufacturing equipment 432 License and distribution rights intangible assets 45,000 Deferred tax liability (15,972 ) Amount attributable to assets acquired $ 34,872 Bargain purchase gain $ (27,336 ) Inventories acquired included raw materials, work-in-progress work-in-process, The fair value of the equipment was determined by consideration of replacement cost and equipment condition and was assigned a useful life of seven years. The fair value of the license and distribution rights intangible assets as amortized in the accompanying consolidated balance sheets were estimated primarily using the “income method,” which starts with a forecast of all expected future cash flows. Some of the more significant assumptions inherent in the development of intangible asset values, from the perspective of a market participant, include: the amount and timing of projected future cash flows (including net revenue, cost of sales, commercial expenses, research and development costs and working capital requirements) as well as estimated contributory asset charges; the discount rate selected to measure the risks inherent in the future cash flows; and the assessment of the asset’s life cycle and the competitive trends impacting the asset, among other factors. The license and distribution rights intangible assets will be amortized over ten years, which approximates the current, remaining patent life of the BELBUCA -related intellectual property. As a result of the business combination, the Company recognized a deferred tax liability of $16.0 million. This deferred tax liability was netted against its deferred tax assets as of December 31, 2017. Because a full valuation allowance has been provided against the Company’s deferred tax assets as it is considered more likely than not that they will not be utilized, the Company released a corresponding amount of its valuation allowance during the year ended December 31, 2017 and recognized a $16.0 million tax benefit in the accompanying consolidated statement of operations. Pro forma impact of acquisition of BELBUCA The following pro forma combined results of operations are provided for the year ended December 31, 2016, as though the BELBUCA acquisition had been completed as of January 1, 2016. These supplemental pro forma results of operations are provided for illustrative purposes only and do not purport to be indicative of the actual results that would have been achieved by the combined company for the period presented or that may be achieved by the combined company in the future. The pro forma results of operations do not include any cost savings or other synergies that resulted, or may result, from the BELBUCA acquisition or any estimated costs that will be incurred to integrate the BELBUCA product line, nor do they reflect the bargain purchase gain recognized. Future results may vary significantly from the results in this pro forma information because of future events and transactions, as well as other factors. (in thousands, except per share data) December 31, Revenue $ 25,010 Net loss $ (201,769 ) Pro forma net loss per common share Basic $ (3.76 ) Diluted $ (3.76 ) The Company’s historical financial information was adjusted to give effect to the pro forma events that were directly attributable to the BELBUCA acquisition and factually supportable. The unaudited pro forma consolidated results include historical revenues and expenses of assets acquired in the acquisition with the following adjustments: • Adjustment to recognize incremental amortization expense based on the fair value of intangibles acquired; • Adjustment to recognize incremental depreciation expense for equipment acquired in the acquisition.

Other License Agreements and Ac

Other License Agreements and Acquired Product Rights	12 Months Ended
	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Other License Agreements and Acquired Product Rights	9. Other license agreements and acquired product rights: Purdue license and supply agreement: On July 12, 2017, the Company, along with Purdue, an Ontario limited partnership, announced that they had executed an exclusive agreement granting to Purdue the licensing, distribution, marketing and sale rights related to BELBUCA in Canada. Financial terms of the Purdue agreement include: (i) total upfront and other cash milestone payments (relating to marketing authorization transfer and certain other marketing- and sales-related milestones) of up to an aggregate of CAD 4.5 million, including approximately CAD 1.5 million (0.5 million CAD and 1.0 million CAD received August 2017 and October 2017, respectfully); (ii) a low double digit percent royalty payable quarterly by Purdue to the Company based on Canadian net sales of BELBUCA, which royalty rate is subject to adjustment in certain circumstances; (iii) an annual royalty fee commencing a period of time after the commercial launch of BELBUCA in Canada, which fee is creditable against royalties payable by Purdue and subject to reduction in certain circumstances; and (iv) payment by Purdue of certain costs incurred to obtain and transfer the marketing authorization for BELBUCA in Canada, a portion of which will be reimbursed by the Company as a reduction of royalties payable by Purdue. On September 12, 2017, the Company announced Health Canada had granted market authorization to formally transfer the Drug Identification Number (DIN) ownership of BELBUCA On January 30, 2018, the Company and Purdue announced that BELBUCA was now commercially available in Canada. The first commercial sale of BELBUCA in Canada triggered a milestone payment to the Company from Purdue in the amount of CAD 1 million, which the Company received March 2018. On January 8, 2019, the Company received the required 60-day notice TTY license and supply agreement On October 7, 2010, the Company announced a license and supply agreement with TTY Biopharm Co., Ltd. (“TTY”) for the exclusive rights to develop and commercialize BEMA Fentanyl in the Republic of China, Taiwan. The agreement results in potential milestone payments to the Company of up to $1.3 million, which include an upfront payment of $0.3 million that was received in 2010. In addition, the Company will receive an ongoing royalty based on net sales. TTY will be responsible for the regulatory filing of BEMA Fentanyl in Taiwan as well as future commercialization in that territory. The term of the agreement with TTY is for the period from October 4, 2010 until the date fifteen years after first commercial sale unless the agreement is extended in writing or earlier terminated as provided for in the agreement. On July 29, 2013, the Company announced the regulatory approval of BEMA Fentanyl in Taiwan, where the product will be marketed under the brand name PAINKYL. The approval in Taiwan resulted in a milestone payment of $0.3 million to the Company, which was received in the third quarter 2013. The Company received cumulative payments totaling $1.5, $1.2 million and $0.9, all which related to royalties based on product purchased in Taiwan by TTY of PAINKYL. Such amounts are recorded as contract revenue in the accompanying consolidated statement of operations for the years ended December 31, 2018, 2017 and 2016, respectively.

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2018
Debt Disclosure [Abstract]
Notes Payable	10. Notes payable: On February 21, 2017, the Company entered into a term loan agreement (the “Term Loan Agreement”) with CRG, as administrative agent and collateral agent, and the lenders named in the Term Loan Agreement (the “Lenders”). The Company utilized approximately $29.4 million of the initial loan proceeds under the Term Loan Agreement to repay all the amounts owed by the Company under the 2015 MidCap Credit Agreement. Upon the repayment of all amounts owed by the Company under the MidCap Credit Agreement, all commitments under the MidCap Credit Agreement were terminated and all security interests granted by the Company and its subsidiary guarantors under the MidCap Credit Agreement were released. Certain warrants issued to MidCap and its affiliates in May 2016 related to the extension of the interest only period under the MidCap Credit Agreement remain outstanding as of December 31, 2018 and will expire, if not earlier exercised in May 2021. Such warrants are exercisable for 84,986 shares of Common Stock at an exercise price of $3.53 per share. During the year ended December 31, 2017, $0.7 million of deferred loan costs arising out of the MidCap Credit Agreement were expensed and recorded as interest expense in the accompanying consolidated statement of operations. Pursuant to the Term Loan Agreement, the Company borrowed $45.0 million from the Lenders as of the Closing Date, and was eligible to borrow up to an additional $15.0 million contingent upon achievement of certain conditions, including: (i) in the case of the first tranche, representing the second potential draw under the Loan Agreement (the “Second Draw”), satisfying both (a) certain minimum net revenue thresholds on or before September 30, 2017 or December 31, 2017 and (b) a certain minimum market capitalization threshold for a period of time prior to the funding of the Second Draw (provided, that if the Company does not achieve the minimum net revenue thresholds necessary for the Second Draw but does achieve a certain minimum market capitalization threshold for a period of time prior to December 31, 2017, the Company would be eligible for a Second Draw funding in the amount of $5.0 million). On December 26, 2017, the Company was eligible and elected to receive the Second Draw for gross proceeds of $15.0 million. After the payoff of the MidCap Credit Agreement, the Company utilized the initial proceeds under the Term Loan Agreement (after deducting loan origination costs and broker and other fees) of approximately $13.7 million, plus any additional amounts borrowed in the future, for general corporate purposes and working capital. The original Term Loan Agreement had a six-year term The Company may prepay all or a portion of the outstanding principal and accrued unpaid interest under the Term Loan Agreement at any time upon prior notice to the Lenders subject to a certain prepayment fees during the first five years of the term (which fees are lowered over time) and no prepayment fee thereafter. In certain circumstances, including a change of control and certain asset sales or licensing transactions, the Company is required to prepay all or a portion of the loan, including the applicable prepayment premium on the amount of the outstanding principal to be prepaid. As security for its obligations under the Term Loan Agreement, on the funding date of the initial borrowing, the Company and the Subsidiary Guarantors entered into a security agreement with CRG whereby the Company and the subsidiary guarantors of the Company under the Term Loan Agreement (the “Subsidiary Guarantors”) granted to CRG, as collateral agent for the Lenders, a lien on substantially all of its assets including intellectual property (subject to certain exceptions). The Term Loan Agreement requires the Company to maintain minimum cash and cash equivalents balance and, each year through the end of 2022, to meet a minimum net annual revenue threshold. The Company is in compliance as of December 31, 2018. In the event that the Company does not meet the minimum net annual revenue threshold, then the Company can satisfy the requirement for that year by raising two (2) times the shortfall by way of raising equity or subordinated debt. The Term Loan Agreement also contains customary affirmative and negative covenants for a credit facility of this size and type, including covenants that limit or restrict the Company’s ability to, among other things (but subject in each case to negotiated exceptions), incur indebtedness, grant liens, merge or consolidate, dispose of assets, make investments, make acquisitions, enter into transactions with affiliates, pay dividends or make distributions, license intellectual property rights on an exclusive basis or repurchase stock. The Term Loan Agreement includes customary events of default that include, among other things, non-payment, inaccuracy The following table represents future maturities of the CRG obligation as of December 31, 2018: 2019 $ — 2020 — 2021 30,892 2022 30,892 Total maturities $ 61,784 Unamortized discount and loan costs (10,132 ) Total notes payable obligation $ 51,652 In connection with the initial borrowing made under the Term Loan Agreement, the Company issued to CRG and certain of its affiliates five separate warrants to purchase an aggregate of 1,701,583 shares of the Common Stock (the “CRG Warrants”). The CRG Warrants are exercisable any time prior to February 21, 2027 at a price of $2.38 per share, with typical provisions for cashless exercises. The exercise of the CRG Warrants could have a dilutive effect to the Common Stock to the extent that the market price per share of the Common Stock, as measured under the terms of the CRG Warrants, exceeds the exercise price of the CRG Warrants. In connection with the Second Draw, the Company issued to CRG and certain of its affiliates warrants to purchase an aggregate of 349,452 shares of the Company’s common stock (the “CRG Second Draw Warrants”). The CRG Second Draw Warrants are exercisable any time prior to December 26, 2027, at a price of $3.42 per share, with typical provisions for cashless exercise and stock-based anti-dilution protection. The exercise of the CRG Second Draw Warrants could have a dilutive effect to the Company’s common stock to the extent that the market price per share of the Company’s common stock, as measured under the terms of the CRG Second Draw Warrants, exceeds the exercise price of the CRG Warrants.

Net Sales by Product

Net Sales by Product	12 Months Ended
	Dec. 31, 2018
Segment Reporting [Abstract]
Net Sales by Product	11. Net sales by product: The Company operates in a single industry engaging in the commercialization of pharmaceutical products principally in the areas of pain management and addiction. Accordingly, the Company’s business is classified as a single reportable segment. The following table presents net sales by product for each of the years ended December 31 (in thousands): Year ended December 31, 2018 2017 2016 BELBUCA $ 45,988 $ 26,980 $ — BUNAVAIL 5,422 7,942 8,266 Net product sales $ 51,410 $ 34,922 $ 8,266

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income Taxes	12. Income taxes: On December 22, 2017, the United States enacted major tax reform legislation, Public Law No. 115-97, one-time The Company recorded federal income tax benefit during 2018 due to the impact of the 2018 Tax Cuts and Jobs Act. For years beginning after December 31, 2017, the Act repeals corporate AMT. The credit becomes refundable in an amount equal to 50% of the excess of the credit for the tax year over the amount of the credit allowable for the year against regular tax liability. The Company recorded state income tax expense of $0.05 million due to state audit findings related to prior periods. The Company has recognized valuation allowances for all deferred tax assets for years ending 2018 and 2017. Reconciliation of the Federal statutory income tax rate of 21% to the effective rate is as follows: 2018 2017 2016 Federal statutory income (benefit) tax rate 21.00 % (34.00 %) 34.00 % 2017 Tax Act, net deferred tax remeasurement — (626.73 ) — State taxes, net of federal benefit (0.11 ) (2.01 ) 2.88 Stock compensation (4.74 ) (5.18 ) (0.61 ) Permanent differences-other (1.33 ) (13.39 ) (1.00 ) North Carolina tax rate change — (32.75 ) — Research and development (“R&D”) credit — 5.54 0.98 Valuation release for bargain purchase gain — (302.23 ) — Other (2.07 ) (1.36 ) (0.47 ) Decrease (increase) in valuation allowance (12.65 ) 709.88 (35.78 ) 0.10 % (302.23 %) 0.00 % The tax effects of temporary differences and net operating losses that give rise to significant components of deferred tax assets and liabilities consist of the following: December 31, Deferred tax assets (liabilities) 2018 2017 Deferred revenue $ — $ — Basis difference in equipment (459 ) (587 ) Basis difference in intangibles (6,045 ) (8,288 ) Accrued liabilities and other 2,246 654 R&D credit 10,980 11,882 AMT credit — 79 Stock options 4,360 6,115 Net operating loss carry-forward 64,376 61,660 75,458 71,515 Less: valuation allowance (75,458 ) (71,515 ) $ — $ — The Company is required to reduce any deferred tax asset by a valuation allowance if, based on an assessment of positive and negative evidence, including estimates of future taxable income necessary to realize future deductible amounts, it is more likely than not (a likelihood of more than 50 percent) that some portion or all of the deferred tax assets will not be realized. The valuation allowance should be sufficient to reduce the deferred tax asset to the amount, which is more likely than not to be realized. As a result, the Company recorded a valuation allowance with respect to all of the Company’s deferred tax assets. The Company has a federal net operating loss carry forward (“NOLs”) of approximately $279 million as of December 31, 2018. Under Section 382 and 383 of the Internal Revenue Code, if an ownership change occurs with respect to a “loss corporation”, as defined, there are annual limitations on the amount of the NOLs and other deductions, which are available to the Company. The portion of the NOLs incurred prior to May 16, 2006 is subject to this limitation. As such, the use of these NOLs to offset taxable income is limited to approximately $1.5 million per year. The Company’s State NOLS are approximately $264 million as of December 31, 2018. These loss carryforwards expire between 2024 and 2037 for federal NOL and 2030 for state NOL generated prior to December 31, 2017. The federal NOL generated in 2018 of $3.28 million will have an indefinite carryforward life due to tax reform. Management has evaluated all other tax positions that could have a significant effect on the financial statements and determined that the Company has no uncertain income tax positions at December 31, 2018. One or more of the Company’s legal entities file income tax returns in the U.S. federal jurisdiction and various U.S. state jurisdictions. The Company’s income tax returns are subject to audit by the tax authorities in those jurisdictions. Significant disputes may arise with authorities involving issues of the timing and amount of deductions, the use of tax credits and allocations of income and expenses among various tax jurisdictions because of differing interpretations of tax laws, regulations and the interpretation of the relevant facts. The Company is no longer subject to U.S. federal or state tax examinations for years ended on or before December 31, 2014.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2018
Federal Home Loan Banks [Abstract]
Stockholders' Equity	13. Stockholders’ equity: Common Stock On August 23, 2017, the Company and Dr. Mark Sirgo entered into a retirement agreement (the “Sirgo Retirement Agreement”). Pursuant to the Sirgo Retirement Agreement, all unvested RSUs previously issued under the Company’s equity incentive plans and held by Dr. Sirgo as of the retirement date were cancelled and, in lieu thereof, Dr. Sirgo was awarded a one-time On January 12, 2018, the Company and Dr. Niraj Vasisht entered into a retirement agreement (the “Vasisht Retirement Agreement”). Pursuant to the Vasisht Retirement Agreement, all unvested RSUs previously issued under the Company’s equity incentive plans and held by Dr. Vasisht as of the retirement date were cancelled and, in lieu thereof, Dr. Vasisht was awarded a one-time The Compensation Committee of the Board of Directors approved in early 2018, equity awards for 2017 in the form of RSUs to its named executive officers (including Drs. Sirgo and Vasisht) and other senior executives. Dr. Sirgo, received 285,305 and Dr. Vasisht received 198,129, respectively, shares of Common Stock in fulfillment of the Company’s contractual obligations. Such shares were issued in 2018. On August 2, 2018, in connection with the Company’s 2018 Annual Meeting of Stockholders, the Company’s stockholders approved, among other matters, to amend the Company’s Certificate of Incorporation to increase the number of authorized shares of Common Stock from 75,000,000 to 125,000,000. On November 9, 2018, The Company filed a shelf registration statement (as amended on January 18, 2019) which registered up to $150 million of the Company’s securities for potential future issuance and such registration statement was effective on February 7, 2019. Preferred Stock and Series A Preferred The Company had authorized five million “blank check” shares of $.001 par value convertible preferred stock. In the event of the Company’s liquidation, dissolution or winding up, holders of the Series A Preferred will receive a payment equal to $.001 per share of Series A Preferred before any proceeds are distributed to the holders of common stock. After the payment of this preferential amount, and subject to the rights of holders of any class or series of capital stock hereafter created specifically ranking by its terms senior to the Series A Preferred, the holders of Series A Preferred will participate ratably in the distribution of any remaining assets with the common stock and any other class or series of our capital stock hereafter created that participates with the common stock in such distributions. At December 31, 2018, 2,093,155 shares of Series A Preferred were outstanding and 2,285,700 shares of “blank check” preferred stock remain authorized but undesignated. There were no conversions of Series A Preferred during the years ended December 31, 2018, 2017 or 2016. Series B Preferred stock financing In May of 2018, the Company closed on the sale of an aggregate of 5,000 shares of the Company’s authorized preferred stock that the Board of Directors of the Company has designated as Series B Non-Voting Convertible Each share of Series B Preferred Stock is convertible into a number of shares of the Company’s common stock at a conversion price of $1.80 per share (subject to adjustment for stock splits and stock dividends as provided in the Certificate of Designation). At the time of closing the then outstanding shares of Series B Preferred Stock were convertible into an aggregate 27,777,778 shares of Common Stock. The Series B Preferred Stock does not contain any price-based anti-dilution protection. The Series B Preferred Stock is convertible at any time at the option of the holder, subject to certain limitations related to beneficial ownership. The Company has the right to deliver a notice to the holders of the Series B Preferred Stock to require conversion of the Series B Preferred Stock into Common Stock. Following an initial forced conversion of the Series B Preferred Stock, every ninety (90) days thereafter, the Company has the right to require the forced conversion of the still outstanding shares of Series B Preferred Stock, subject to certain limitations related to beneficial ownership. During the year ended December 31, 2018, a cumulative total of 1,900 shares of Series B Preferred Stock from various holders were converted into 10,555,556 shares of Common Stock. As of December 31, 2018, 3,100 shares of Series B Preferred Stock are outstanding. The Series B Preferred Stock issued in May 2018 contained a contingent beneficial conversion feature (“BCF”) that was recognized during the year ending December 31, 2018 upon the August 2018 stockholder approval, which eliminated the contingency. The Company evaluated its convertible preferred stock in accordance with provisions of ASC 815, Derivatives and Hedging, including consideration of embedded derivatives requiring bifurcation. The issuance of the Series B Preferred Stock generated a BCF, which arises when a debt or equity security is issued with an embedded conversion option that is beneficial to the investor or in the money at inception because the conversion option has an effective strike price that is less than the market price of the underlying stock at the commitment date. As a result, the intrinsic value of the conversion option , totaling $12.5 million, was recorded as a reduction to additional paid-in Restricted stock units During the year ended December 31, 2018, 2,034,261 RSUs, were granted to members of the Company’s executive officers, board of directors, certain employees and retiring officers, with a fair market value of approximately $4.7 million. The fair value of restricted units is determined using quoted market prices of the Common Stock and the number of shares expected to vest. These RSUs were issued under the Company’s 2011 Equity Incentive Plan, as amended, and vest as following: (i) For executive officers, half of the grant vests in equal installments over three years and the remaining half vests subject to performance criteria over three years, (ii) for employees, the grants immediately vested in full October 2018, (iii) for the board of directors grants vest ratably from August 2018 to August 2022, and (iv) and for retiring officers, the grants vested immediately vested in full February and March 2018. Restricted stock activity during the year ended December 31, 2018 was as follows: Number of Weighted Outstanding at January 1, 2018 4,706,895 $ 5.20 Granted: Executive officers 1,183,750 2.25 Directors 469,261 2.59 Employees 381,250 2.28 Vested (1,863,731 ) 2.57 Forfeitures (591,398 ) 2.46 Conversions (2,119,925 ) 2.72 Outstanding at December 31, 2018 2,166,102 $ 2.59 Performance Long Term Incentive Plan In December 2012, the Company’s Board of Directors (the “Board”) approved the BDSI Performance Long Term Incentive Plan (“LTIP”). The LTIP is designed as an incentive for the Company’s senior management to generate revenue for the Company. The LTIP consists of RSUs (which are referred to in this context as Performance RSUs) which are rights to acquire shares of Common Stock. All Performance RSUs granted under the LTIP will be granted under the Company’s 2011 Equity Incentive Plan (as the same may be amended, supplemented or superseded from time to time) as “Performance Compensation Awards” under such plan. The participants in the LTIP are either named executive officers or senior officers of the Company. The term of the LTIP began with the Company’s fiscal year ended December 31, 2012 and lasts through the fiscal year ending December 31, 2019. The total number of Performance RSUs covered by the LTIP is 1,078,000, of which 978,000 were awarded in 2012 (with 100,000 Performance RSUs being reserved for future hires and of that reserve, 35,000 Performance RSUs were awarded in 2015). No additional Performance RSUs were awarded in 2017 or 2018. The Performance RSUs under the LTIP did not vest upon granting, but instead are subject to potential vesting each year over the 8-year pre-defined 10-K. Stock options The Company has a 2011 Equity Incentive Plan. During the 2017 Annual Meeting of Stockholders (the “Annual Meeting”), stockholders approved an amendment to the Company’s 2011 Equity Incentive Plan to increase the number of shares of common stock authorized for issuance under the plan by 7,100,000 shares from 11,050,000 to 18,150,000. An additional 523,854 shares of Common Stock underlying options previously granted under the Company’s Amended and Restated 2001 Incentive Plan remain outstanding and exercisable as of December 31, 2018. The Company’s Amended and Restated 2001 Incentive Plan expired in July 2011 and no new securities may be issued thereunder. Options may be awarded during the ten-year During the years ended December 31, 2018, 2017 and 2016, Company employees, directors and affiliates exercised approximately 0.4 million, 0.2 million and 0.1 million stock options, respectively, with net proceeds to the Company of approximately $0.7 million, 0.4 million and $0.3 million, respectively. Stock option activity for the years ended December 31, 2018, 2017 and 2016 is as follows: Number of Weighted Average Aggregate Outstanding at January 1, 2016 3,397,529 $ 5.42 $ 3,124 Granted in 2016: Officers and Directors 95,000 $ 2.34 Others 558,373 3.12 Exercised (147,425 ) 2.01 Forfeitures (434,486 ) 13.17 Outstanding at December 31, 2016 3,468,991 $ 4.14 $ 0 Granted in 2017: Officers and Directors 83,658 $ 2.64 Others 873,017 1.96 Exercised (202,519 ) 2.17 Forfeitures (1,510,193 ) 5.13 Outstanding at December 31, 2017 2,712,954 $ 2.98 $ 1,190 Granted in 2018: Officers and Directors 1,249,817 $ 2.49 Others 1,299,360 2.60 Exercised (350,441 ) 2.00 Forfeitures (502,186 ) 3.48 Outstanding at December 31, 2018 4,406,004 $ 3.19 $ 4,172 Options outstanding at December 31, 2018 are as follows: Range of Exercise Prices Number Weighted Average Weighted Average Aggregate $1.00 – 5.00 3,948,887 7.72 $ 2.70 $5.01 – 10.00 387,361 4.78 $ 5.91 $10.01 – 15.00 38,756 6.15 $ 13.09 $15.01 – 20.00 31,000 6.00 $ 16.20 4,406,004 $ 4,172 Options exercisable at December 31, 2018 are as follows: Range of Exercise Prices Number Weighted Average Weighted Average Aggregate $1.00 – 5.00 1,196,693 4.07 $ 3.15 $5.01 – 10.00 375,722 4.71 $ 6.10 $10.01 – 15.00 38,756 6.15 $ 13.09 $15.01 – 20.00 31,000 5.80 $ 16.20 1,642,171 $ 653 The weighted average grant date fair value of options granted during the years ended December 31, 2018, 2017 and 2016 was $1.57, $1.46 and $1.75, respectively. There were no options granted during the years ended December 31, 2018, 2017 or 2016 whose exercise price was lower than the estimated market price of the stock at the grant date. Nonvested stock options as of December 31, 2018, and changes during the year then ended, are as follows: Nonvested Shares Shares Weighted Average Intrinsic Nonvested at January 1, 2018 885,484 Granted 2,549,177 Vested (209,500 ) Forfeited (461,328 ) Nonvested at December 31, 2018 2,763,833 $ 1.54 $ 5,979 As of December 31, 2018, there was approximately $6.9 million of unrecognized compensation cost related to unvested share-based compensation awards granted. These costs will be expensed over the next four years. Stock-based compensation During the year ended December 31, 2018, a total of 2,549,177 options to purchase Common Stock, with an aggregate fair market value of approximately $3.9 million, were granted to Company employees and directors. The options granted have a term of 10 years from the grant date and vest ratably between a one and three-year period. The fair value of each option is amortized as compensation expense evenly through the vesting period. Warrants: The Company has granted warrants to purchase shares of Common Stock. Warrants may be granted to affiliates in connection with certain agreements. During the year ended December 31, 2016, the Company granted warrants to purchase 84,986 shares of Common Stock at an exercise price of $3.53 per share to Midcap and its affiliates in connection with the Company’s extension agreement with MidCap. The warrants were valued using the Black-Scholes Model, which fair value is approximately $0.05 million. As of December 31, 2018, 84,986 warrants remain outstanding. In February 2017, the Company granted warrants to purchase 1,701,583 shares of Common Stock at an exercise price of $2.38 per share to CRG and certain of its affiliates in connection with the Company’s term loan agreement with CRG. The warrants were valued using the Black-Scholes Model, which fair value is approximately $4.5 million. In December 2017, the Company granted warrants to purchase 349,451 shares of Common Stock at an exercise price of $3.42 per share to CRG and certain of its affiliates in connection with the Company’s 2 nd

Earnings per Common Share

Earnings per Common Share	12 Months Ended
	Dec. 31, 2018
Earnings Per Share [Abstract]
Earnings per Common Share	14. Earnings per common share: The following is a reconciliation of the numerators and denominators of the basic and diluted earnings per common share computations for the years ended December 31, 2018, 2017 and 2016. December 31, 2018 2017 2016 Basic: Net (loss) income $ ( 33,867 ) $ 5,285 $ (67,138 ) Less deemed dividend related to beneficial conversion feature on Series B Preferred Stock (12,500 ) — — Net (loss) income attributable to common stockholders, basic $ (46,367 ) $ 5,285 $ (67,138 ) Weighted average common shares outstanding 63,165,063 55,355,802 53,679,134 Basic (loss) income per common share $ (0.73 ) $ 0.10 $ (1.25 ) December 31, 2018 2017 2016 Diluted: Effect of dilutive securities: Net (loss) income attributable to common stockholders, diluted $ (46,367 ) $ 5,285 $ (67,138 ) Weighted average common shares outstanding 63,165,063 55,355,802 53,679,134 Effect of dilutive options and warrants — 1,046,677 — Diluted weighted average common shares outstanding 63,165,063 56,402,479 53,679,134 Diluted (loss) income per common share $ (0.73 ) $ 0.09 $ (1.25 ) Basic earnings per common share is calculated using the weighted average shares of Common Stock outstanding during the period. Common equivalent shares from stock options, RSUs, warrants and convertible preferred stock using the treasury stock method, are also included in the diluted per share calculations unless the effect of inclusion would be antidilutive. During the years ended December 31, 2018, 2017 and 2016, outstanding stock options, RSUs, warrants and convertible preferred stock of 28,424,998, 6,531,346 and 10,228,929, respectively, were not included in the computation of diluted earnings per common share, because to do so would have had an antidilutive effect because the outstanding exercise prices were greater than the average market price of the common shares during the relevant periods. Included in the year ended December 31, 2018 are the Series B shares as converted to common stock. The following is the total outstanding options, RSUs and warrants for the years ended December 31, 2018, 2017 and 2016, respectively. 2018 2017 2016 Options, RSUs, warrants and convertible preferred stock to purchase Common Stock 10,739,378 9,555,869 10,228,929

Retirement Plan

Retirement Plan	12 Months Ended
	Dec. 31, 2018
Retirement Benefits [Abstract]
Retirement Plan	15. Retirement plan: The Company sponsors a defined contribution retirement plan under Section 401(k) of the Internal Revenue Code. The plan covers all employees who meet certain eligibility and participation requirements. Participants may contribute up to 90% of their eligible earnings, as limited by law. The Company makes a matching contribution equal to 100% on the first 5% of participant contributions to the plan. The Company made contributions of approximately $0.8 million, $0.5 million and $0.4 million in years, 2018, 2017 and 2016.

Separation Agreement

Separation Agreement	12 Months Ended
	Dec. 31, 2018
Compensation Related Costs [Abstract]
Separation Agreement	16. Separation agreement: De Paolantonio separation agreement On January 23, 2019, the Company entered into a Transitional Service and Separation Agreement (the “Separation Agreement”) with Mr. De Paolantonio, the Company’s former Chief Financial Officer and Treasurer. Unless Mr. De Paolantonio resigns or his employment is terminated earlier, Mr. De Paolantonio will continue as a senior advisor to the Company until April 30, 2019, at which time his employment with the Company will end (the “Retirement Date”). The Separation Agreement provides for, among other things, Mr. De Paolantonio to (i) continue to receive his current base salary, (ii) remain eligible to participate in the Company’s group employee benefit plans as a regular full-time employee, and (iii) continue to vest in his outstanding equity awards until his Retirement Date. At the termination of his employment with the Company, provided that, among other things, Mr. De Paolantonio is not terminated by the Company for “cause,” Mr. De Paolantonio will be entitled to receive (a) a one-time

Commitments and contingencies

Commitments and contingencies	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	17. Commitments and contingencies: Operating leases Since November 2007, the Company has leased space for their corporate office. Lease expense for the corporate office was $0.3 million for each of the years ended December 31, 2018, 2017 and 2016, respectively. The Company leased new space for their corporate offices, which began March 2015 for 89 months. The future minimum commitment on the new operating lease at December 31, 2018 is as follows: Years ending December 31, 2019 $ 351 2020 360 2021 370 2022 219 $ 1,300 Indemnifications The Company’s directors and officers are indemnified against costs and expenses related to stockholder and other claims (i.e., only actions taken in their capacity as officers and directors) that are not covered by the Company’s directors’ and officers’ insurance policy. This indemnification is ongoing and does not include a limit on the maximum potential future payments, nor are there any recourse provisions or collateral that may offset the cost. Post marketing requirements On October 5, 2017, the Company entered a subsequent party acknowledgement relating to its participation in the Opioid PMR Consortium (the “OPC”). The participants are member companies, collectively undertaking various observational and clinical studies to satisfy certain post-marketing requirements by the FDA as holders of a NDA for extended-release and long-acting opioid analgesics. As a requirement of joining the OPC, the Company was required to pay its share of the previous expenses incurred and funded by the existing member companies. The Company’s pro-rata Certain rights of CDC IV The Company and CDC IV are parties to the CDLA pursuant to which CDC IV has previously provided funds to the Company for the development of the Company’s ONSOLIS product. CDC IV is entitled to receive a mid-single In September 2007, in connection with CDC IV’s consent to the North American Mylan transaction, the Company, among other transactions with CDC IV, granted CDC IV a 1% royalty on net sales of the next BEMA product, which was BUNAVAIL. CDC IV’s right to the royalty shall immediately terminate at any time if annual net sales of BUNAVAIL equal less than $7.5 million in any calendar year following the third anniversary of initial launch of the product and CDC IV receives $0.02 million in three (3) consecutive quarters as payment for CDC IV’s one percent (1%) royalty during such calendar year. The Company records such royalties as costs of sales occur. In April 2016, CDC IV exercised its right pursuant to the Royalty Purchase and Amendment Agreement to exchange its royalty rights to the next BEMA product which was BUNAVAIL, in favor of royalty rights to the Substitute BEMA product which is BELBUCA (the CDC IV Option). Indivior PLC (formerly RB Pharmaceuticals Ltd.) and Aquestive Therapeutics (formerly MonoSol Rx) Litigation related to BUNAVAIL Reckitt Benckiser, Inc., RB Pharmaceuticals Limited, and Aquestive (collectively, the RB Plaintiffs) (and the Company’s commercial partner) relating to the Company’s BUNAVAIL product in the United States District Court for the District of New Jersey for alleged patent infringement. The RB Plaintiffs claim that BUNAVAIL, whose formulation and manufacturing processes have never been disclosed publicly, infringes its patent U.S. Patent No. 8,765,167 (the ‘167 Patent. As with prior actions by the RB Plaintiffs, the Company believes this is another anticompetitive attempt by the RB Plaintiffs to distract our efforts from commercializing BUNAVAIL. The Company strongly refutes as without merit the RB Plaintiffs’ assertion of patent infringement. On the Company’s motion, this case was transferred to the Eastern District of North Carolina. A Joint Motion to Stay the case was granted and the case is now stayed until a final resolution of the ‘167 IPRs discussed directly below. The Company will continue to vigorously defend this case. On October 28, 2014, the Company filed multiple IPR petitions on certain claims of the ‘167 Patent. The USPTO instituted three of the four IPR petitions. The PTAB upheld the claims and denied collateral estoppel applied to the PTAB decisions in March 2016. The Company appealed to Court of Appeals for the Federal Circuit. The USPTO intervened with respect to whether collateral estoppel applied to the PTAB. On June 19, 2018, the Company filed a motion to remand the case for further consideration by the PTAB in view of intervening authority. On July 31, 2018, the Federal Circuit vacated the decisions, and remanded the ‘167 Patent IPRs for further consideration on the merits. Litigation related to BELBUCA On January 13, 2017, Aquestive filed a complaint in the United States District Court for the District of New Jersey alleging BELBUCA infringes the ‘167 Patent. In lieu of answering the complaint, the Company filed motions to dismiss the complaint and, in the alternative, to transfer the case to the EDNC. On July 25, 2017, the New Jersey Court administratively terminated the case pending the parties submission of a joint stipulation of transfer because the District of New Jersey was an inappropriate venue. This case was later transferred to the Delaware District Court. On October 31, 2017 the Company filed motions to dismiss the complaint and, in the alternative, to transfer the case to the EDNC. On October 16, 2018, denying the motion to dismiss as moot, the Delaware District Court granted the Company’s motion to transfer the case to the EDNC. The case is now pending in the EDNC. The Company strongly refutes as without merit Aquestive’s assertion of patent infringement and will vigorously defend the lawsuit. Teva Pharmaceuticals USA (formerly Actavis) On February 8, 2016, the Company received a notice relating to a Paragraph IV certification from Teva Pharmaceuticals USA (“Teva”) (formerly Actavis) seeking to find invalid three Orange Book listed patents relating specifically to BUNAVAIL. The Paragraph IV certification related to an Abbreviated New Drug Application (the “ANDA”) filed by Teva with the U.S Food and Drug Administration (“FDA”) for a generic formulation of BUNAVAIL. The patents subject to Teva’s certification were U.S. Patent No. 7,579,019 (the “‘019 Patent”), U.S. Patent No. 8,147,866 (the “‘866 Patent”) and 8,703,177 (the “‘177 Patent”). On October 12, 2017, the Company announced that it had entered into a settlement agreement with Teva that resolved the Company’s BUNAVAIL patent litigation against Teva pending in the U.S. District Court for the District of Delaware. As part of the Settlement Agreement, which is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice, the Company had entered into a non-exclusive The Company received notices regarding Paragraph IV certifications from Teva on November 8, 2016, November 10, 2016, and December 22, 2016, seeking to find invalid two Orange Book listed patents relating specifically to BELBUCA. The Paragraph IV certifications relate to three ANDAs filed by Teva with the FDA for a generic formulation of BELBUCA. The patents subject to Teva’s certification were the ‘019 Patent and the ‘866 Patent. The Company filed complaints in Delaware against Teva on December 22, 2016 and February 3, 2017 in which the Company asserted against Teva the ‘019 Patent and the ‘866 Patent. Teva did not contest infringement of the claims of the ‘019 Patent and did not contest infringement of the claims of the ‘866 Patent. In February 2018, the Company announced that it had entered into a settlement agreement with Teva that resolved the Company’s BELBUCA patent litigation against Teva pending in the U.S. District Court for the District of Delaware. As part of the settlement agreement, which is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice, the Company had granted Teva a non-exclusive patents-in-suit Alvogen On September 7, 2018, the Company filed a complaint for patent infringement in Delaware against Alvogen Pb Research & Development LLC, Alvogen Malta Operations Ltd., Alvogen Pine Brook LLC, Alvogen, Incorporated, and Alvogen Group, Incorporated (collectively, “Alvogen”), asserting that Alvogen infringes the Company’s Orange Book listed patents for BELBUCA, including U.S. Patent Nos. 8,147,866 and 9,655,843, both expiring in July of 2027, and U.S. Patent No. 9,901,539, expiring in December of 2032. This complaint follows receipt by the Company on July 30, 2018 of a Paragraph IV Patent Certification from Alvogen stating that Alvogen had filed an ANDA with the FDA for a generic version of BELBUCA Buccal Film (75 mcg, 150 mcg, 300 mcg, 450 mcg, 600 mcg, 750 mcg and 900 mcg). Because the Company initiated a patent infringement suit to defend the patents identified in the Paragraph IV notice within 45 days after receipt of the Paragraph IV Certification, the FDA is prevented from approving the ANDA until the earlier of 30 months or a decision in the case that each of the patents is not infringed or invalid. Alvogen’s notice letter also does not provide any information on the timing or approval status of its ANDA. In its Paragraph IV Certification, Alvogen does not contest infringement of at least several independent claims of each of the ’866, ’843, and ’539 patents. Rather, Alvogen advances only invalidly arguments for these independent claims. The Company believes that it will be able to prevail on the Company’s claims of infringement of these patents, particularly as Alvogen does not contest infringement of certain claims of each patent. Additionally, as the Company has done in the past, it intends to vigorously defend its intellectual property against assertions of invalidity. Each of the three patents carry a presumption of validity, which can only be overcome by clear and convincing evidence. 2018 Arkansas Opioid Litigation On March 15, 2018, the State of Arkansas, and certain counties and cities in that State, filed an action in the Circuit Court of Arkansas, Crittenden County against multiple manufacturers, distributors, retailers, and prescribers of opioid analgesics, including our Company. The Company was served with the complaint on April 27, 2018. The complaint specifically alleged that the Company licensed its branded fentanyl buccal soluble film ONSOLIS to Collegium, and Collegium is also named as a defendant in the lawsuit. ONSOLIS is not presently sold in the United States and the license agreement with Collegium was terminated prior to Collegium launching ONSOLIS in the United States. Therefore, on June 28, 2018, the Company moved to dismiss the case against it and most recently, on July 6, 2018, the plaintiffs filed a notice to voluntarily dismiss the Company from the Arkansas case, without prejudice. Chemo Research, S.L On March 1, 2019, the Company filed a complaint for patent infringement in Delaware against Chemo Research, S.L., Insud Pharma S.L., IntelGenx Corp., and IntelGenx Technologies Corp. (collectively, “Defendants”), asserting that the Defendants infringe its Orange Book listed patents for BELBUCA, including U.S. Patent Nos. 8,147,866 and 9,655,843, both expiring in July of 2027, and U.S. Patent No. 9,901,539 expiring December of 2032. This complaint follows a receipt by the Company on January 31, 2019, of a Notice Letter from Chemo Research S.L. stating that it has filed with the FDA an ANDA containing a Paragraph IV Patent Certification, for a generic version of BELBUA Buccal Film in strengths 75 mcg, 150 mcg, 300 mcg, 450 mcg, and 900 mcg. Because the Company initiated a patent infringement suit to defend the patents identified in the Notice Letter within 45 days after receipt, the FDA is prevented from approving the ANDA until the earlier of 30 months or a decision in the case that each of the patents is not infringed or invalid. Chemo Research S.L.’s Notice Letter also does not provide any information on the timing or approval status of its ANDA. The Company believes that it will be able to prevail in this lawsuit. As it has done in the past, the Company intends to vigorously defend its intellectual property against assertions of invalidity.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	18. Subsequent events: On January 15, 2019, the Company announced the appointment of Terry Coelho as Chief Financial Officer. Ms. Coelho will also serve as the Company’s principal financial officer and principal accounting officer. Ms. Coelho replaced Ernest De Paolantonio in these positions effective as of January 15, 2019. Mr. De Paolantonio will remain at the Company past such date in order to allow for an orderly transition.

Selected Quarterly Results (Una

Selected Quarterly Results (Unaudited)	12 Months Ended
	Dec. 31, 2018
Quarterly Financial Information Disclosure [Abstract]
Selected Quarterly Results (Unaudited)	SELECTED QUARTERLY RESULTS (UNAUDITED) The following table sets forth certain quarterly financial data for the periods indicated (in thousands, except per share data): Quarter Ended March 31, June 30, September 30, December 31, Revenue $ 11,281 $ 12,175 $ 14,156 $ 18,028 Gross profit 7,866 7,609 10,377 14,005 Loss from operations (8,123 ) (7,266 ) (3,811 ) (4,448 ) Net loss (10,709 ) (9,770 ) (18,880 ) (7,008 ) Basic loss per share (0.18 ) (0.16 ) (0.29 ) (0.13 ) Diluted loss per share (0.18 ) (016 ) (0.29 ) (0.13 ) Quarter Ended March 31, June 30, September 30, December 31, Revenue $ 29,478 $ 8,744 $ 11,253 $ 12,510 Gross profit 23,833 4,573 6,808 7,275 Income (loss) from operations 7,903 (12,987 ) (10,045 ) (14,291 ) Net income (loss) 48,325 (14,879 ) (11,951 ) (16,210 ) Basic income (loss) per share 0.89 (0.27 ) (0.21 ) (0.31 ) Diluted income (loss) per share 0.87 (0.27 ) (0.21 ) (0.30 ) Quarter Ended March 31, June 30, September 30, December 31, Revenue $ 3,040 $ 5,004 $ 3,571 $ 3,931 Gross profit 490 910 1,257 1,631 Loss from operations (17,942 ) (15,594 ) (15,199 ) (15,200 ) Net loss (18,733 ) (16,486 ) (15,977 ) (15,942 ) Basic loss per share (0.35 ) (0.31 ) (0.30 ) (0.29 ) Diluted loss per share (0.35 ) (0.31 ) (0.30 ) (0.29 )

Valuation and Qualifying Accoun

Valuation and Qualifying Accounts and Reserves	12 Months Ended
	Dec. 31, 2018
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
Valuation and Qualifying Accounts and Reserves	SCHEDULE II – VALUATION AND QUALIFYING ACCOUNTS AND RESERVES Balance at Charged Charged to Deductions Balance at (In thousands) Description Valuation allowance for deferred tax assets Year ended December 31, 2018: $ 71,515 $ 3,943 $ — $ — $ 75,458 Year ended December 31, 2017: $ 109,030 $ (37,515 ) $ — $ — $ 71,515 Year ended December 31, 2016: $ 84,960 $ 24,070 $ — $ — $ 109,030 Allowance for rebates Year ended December 31, 2018: $ 5,648 $ 37,071 $ 813 $ (31,270 ) $ 12,261 Year ended December 31, 2017: $ 3,842 $ 17,236 $ (132 ) $ (15,298 ) $ 5,648 Year ended December 31, 2016: $ 4,470 $ (1,204 ) $ 11,501 $ (10,925 ) $ 3,842 Allowance for price adjustments and chargebacks Year ended December 31, 2018: $ 3,925 $ 13,033 $ — $ (12,940 ) $ 4,018 Year ended December 31, 2017: $ 602 $ 6,738 $ (3 ) $ (3,412 ) $ 3,925 Year ended December 31, 2016: $ 383 $ 36 $ 1,711 $ (1,528 ) $ 602 Allowance for inventory obsolescence Year ended December 31, 2018: $ 243 $ (56 ) $ — $ — $ 187 Year ended December 31, 2017: $ — $ 243 $ — $ — $ 243 Year ended December 31, 2016: $ — $ — $ — $ — $ —

Nature of Business and Summar_2

Nature of Business and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Organization	Organization BioDelivery Sciences International, Inc. and subsidiaries (the “Company”) was incorporated in the State of Indiana on January 6, 1997 and reincorporated as a Delaware corporation in 2002. The Company’s subsidiaries are Arius Pharmaceuticals, Inc., a Delaware corporation (“Arius One”) and Arius Two, Inc., a Delaware corporation (“Arius Two”), each of which are wholly-owned, and its majority-owned subsidiary, Bioral Nutrient Delivery, LLC, a Delaware limited liability company (“BND”). The Company is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain. The Company has built a portfolio of products utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA ® The Company’s historical clinical and regulatory development strategy has focused primarily on its ability to use the U.S. Food and Drug Administration’s (“FDA’s”) 505(b)(2) approval process to obtain more timely and efficient approval of new formulations of previously approved, active therapeutics incorporated into the Company’s drug-delivery technology. As used herein, the Company’s common stock, par value $.001 per share, is referred to as the “Common Stock” and the Company’s preferred stock, par value $0.001 per share, is referred to as the “Preferred Stock”.
Principles of consolidation	Principles of consolidation The consolidated financial statements include the accounts of the Company, Arius One, Arius Two and BND. For each period presented BND has been an inactive subsidiary. All significant inter-company balances and transactions have been eliminated.
Use of estimates in financial statements	Use of estimates in financial statements The preparation of the accompanying consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. The Company reviews all significant estimates affecting the consolidated financial statements on a recurring basis and records the effect of any necessary adjustments prior to their issuance. Significant estimates of the Company include: revenue recognition, sales allowances such as returns of product sold, government program rebates, customer coupon redemptions, wholesaler/pharmacy discounts, product service fees, rebates and chargebacks, sales bonuses, stock-based compensation, determination of fair values of assets and liabilities relating to business combinations, and deferred income taxes.
Certain risks, concentrations and uncertainties	Certain risks, concentrations and uncertainties The Company relies on certain materials used in its development and third-party manufacturing processes, most of which are procured from three contract manufacturers and two active pharmaceutical ingredient (“API”) suppliers for BELBUCA and BUNAVAIL ® In addition, the Company utilizes only two contract manufacturers to create the BELBUCA and BUNAVAIL laminates and only one contract manufacturer to package the laminates into final product. Although the Company has long term supply agreements with these two vendors, any problems or regulatory issues at either of these vendors could create significant BELBUCA and BUNAVAIL supply delays. Amounts due to these vendors represented approximately 6.3% and 22.8% of total accounts payable as of December 31, 2018 and 2017, respectively. Key components used in the manufacture of ONSOLIS ® The Company sells its BELBUCA and BUNAVAIL products primarily to large national wholesalers, which in turn may resell the products to smaller or regional wholesalers, retail pharmacies, chain drug stores, government agencies and other third parties. The following table lists the Company’s customers that individually comprise greater than 10% of total accounts receivable: December 31, Customers 2018 2017 Customer A 47 % 47 % Customer B 22 % 22 % Customer C 25 % 26 % Total 94 % 95 % These three customers accounted for 92%, 92% and 91% of total annual sales during the years ended December 31, 2018, 2017 and 2016 respectively.
Cash	Cash The Company places cash on deposit with financial institutions in the United States. The Federal Deposit Insurance Corporation covers $0.25 million for substantially all depository accounts. As of December 31, 2018, the Company had approximately $43.6 million, which exceeded these insured limits. As of December 31, 2017, the Company had approximately $21.2 million, which exceeded these insured limits.
Accounts receivable	Accounts receivable The Company typically requires its customers to remit payments within the first 30 to 37 days, depending on the customer and the products purchased and agreed upon terms. In addition, the Company offers wholesale distributors a prompt payment discount if they make payments within these deadlines. This discount is generally 2% but may be higher in some instances due to product launches or customer and/or industry expectations. Because the Company’s wholesale distributors typically take the prompt payment discount, the Company accrues 100% of the prompt payment discounts, based on the gross amount of each invoice, at the time of sale, and the Company applies earned discounts at the time of payment. The allowance for prompt payment discounts was $0.3 million and $0.2 million as of December 31, 2018 and 2017, respectively. The Company performs ongoing credit evaluations and does not require collateral. As appropriate, the Company establishes provisions for potential credit losses. There were no allowances for doubtful accounts as of December 31, 2018 or 2017. The Company writes off accounts receivable when management determines they are uncollectible and credits payments subsequently received on such receivables to bad debt expense in the period received.
Inventory	Inventory Inventories are stated at the lower of cost or net realizable value with costs determined for each batch under the first-in, first-out On a quarterly basis, the Company analyzes its inventory levels and records allowances for inventory that has become obsolete, inventory that has a cost basis more than the expected net realizable value and inventory that is more than expected demand based upon projected product sales. The Company recorded a $0.2 million in reserve for inventory obsolescence as of December 31, 2018, and 2017. Inventory is composed of the following at December 31: 2018 2017 Raw Materials & Supplies $ 645 $ 1,338 Work-in-process 2,093 3,135 Finished Goods 2,855 1,861 Finished Goods Reserve (187 ) (243 ) Total Inventories $ 5,406 $ 6,091
Property and equipment	Property and equipment The Company records property and equipment at cost less accumulated depreciation, which is computed on a straight-line basis over its estimated useful lives, generally 3 to 10 years. The Company evaluates the carrying value of equipment when events or changes in circumstances indicate the related carrying amount may not be recoverable. The Company has certain manufacturing equipment that isn’t currently in production, which has been deemed idle. There was no impairment of equipment recorded during the year ended December 31, 2018 or 2017.
Intangibles and goodwill	Intangibles and goodwill The Company reviews intangible assets with finite lives (“other intangible assets”) for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company uses an estimate of the undiscounted cash flows over the remaining life of its other intangible assets, or related group of assets where applicable, in measuring whether the assets to be held and used will be realizable. In the event of impairment, the Company would discount the future cash flows using its then estimated incremental borrowing rate to estimate the amount of the impairment. There were no impairment charges recognized on finite lived intangibles in 2018, 2017 or 2016. Intangible assets with finite useful lives are amortized over the estimated useful lives as follows: Estimated Licenses 15 years BELBUCA license and distribution rights 10 years U.S. product rights 8-12 years EU product rights 7-11 Goodwill is evaluated for impairment at least annually or more frequently if events or changes in circumstances indicate that the carrying amount may not be recoverable. During the evaluation of the potential impairment of goodwill, either a qualitative or a quantitative assessment may be performed. If a qualitative evaluation determines that it is more likely than not that no impairment exists, then no further analysis is performed. If a qualitative evaluation is unable to determine whether it is more likely than not that impairment has occurred, a quantitative evaluation is performed. If the carrying value exceeds the fair value, an impairment charge is recorded based on that difference. There were no goodwill impairment charges in 2018, 2017 or 2016.
Revenue recognition	Revenue recognition Product sales As discussed further below in Note 2, effective January 1, 2018, the Company adopted Accounting Standards Update (“ASU”) 2014-09, Performance obligations A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in Topic 606. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The majority of the Company’s product sales contracts have a single performance obligation as the promise to transfer the individual goods is not separately identifiable from other promises in the contracts and, therefore, not distinct. The Company’s performance obligations are satisfied at a point in time. The multiple performance obligations are not allocated based off of the obligations but based off of standard selling price. Adjustments to product sales The Company recognizes product sales net of estimated allowances for rebates, price adjustments, returns, chargebacks and prompt payment discounts. A significant majority of the Company’s adjustments to gross product revenues are the result of accruals for its commercial contracts, retail consumer subsidy programs, and Medicaid rebates. The Company establishes allowances for estimated rebates, chargebacks and product returns based on numerous qualitative and quantitative factors, including: • the number of and specific contractual terms of agreements with customers; • estimated levels of inventory in the distribution channel; • historical rebates, chargebacks and returns of products; • direct communication with customers; • anticipated introduction of competitive products or generics; • anticipated pricing strategy changes by the Company and/or its competitors; • analysis of prescription data gathered by a third-party prescription data provider; • the impact of changes in state and federal regulations; and • the estimated remaining shelf life of products. In its analyses, the Company uses prescription data purchased from a third-party data provider to develop estimates of historical inventory channel sell-through. The Company utilizes an internal analysis to compare historical net product shipments to estimated historical prescriptions written. Based on that analysis, management develops an estimate of the quantity of product in the channel which may be subject to various rebate, chargeback and product return exposures. To estimate months of ending inventory in the Company’s distribution channel, the Company divides estimated ending inventory in the distribution channel by the Company’s recent prescription data, not considering any future anticipated demand growth beyond the succeeding quarter. Monthly for each product line, the Company prepares an internal estimate of ending inventory units in the distribution channel by adding estimated inventory in the channel at the beginning of the period, plus net product shipments for the period, less estimated prescriptions written for the period. This is done for each product line by applying a rate of historical activity for rebates, chargebacks and product returns, adjusted for relevant quantitative and qualitative factors discussed above, to the potential exposed product estimated to be in the distribution channel. In addition, the Company receives daily information from the wholesalers regarding their sales and actual on hand inventory levels of the Company’s products. This enables the Company to execute accurate provisioning procedures. Product returns 18-month Rebates Price adjustments and chargebacks The Company, from time to time, offers certain promotional product-related incentives to its customers. These programs include certain product incentives to pharmacy customers and other sales stocking allowances. The Company has voucher programs for BELBUCA and BUNAVAIL whereby the Company offers a point-of-sale Prompt payment discounts Gross to net accruals License and development agreements The Company periodically enters into license and development agreements to develop and commercialize its products. The arrangements typically are multi-deliverable arrangements that are funded through upfront payments, milestone payments and other forms of payment. The Company currently has multiple license and development agreements that are described in notes 7, 9 and 10. Depending on the nature of the contract these revenues are classified as research and development reimbursements or contract revenue.
Cost of sales	Cost of sales Cost of sales includes the direct costs attributable to the production of BELBUCA and BUNAVAIL. It includes raw materials, production costs at the Company’s three contract manufacturing sites, quality testing directly related to the products, and depreciation on equipment that the Company has purchased to produce BELBUCA and BUNAVAIL. It also includes any batches not meeting specifications and raw material yield losses. Yield losses and batches not meeting specifications are expensed as incurred. Cost of sales is recognized when sold to the wholesaler from our distribution center. For BREAKYL and PAINKYL (the Company’s out-licensed
Research and development expenses	Research and development expenses Research and development expenses have historically consisted of product development expenses incurred in identifying, developing and testing product candidates. Product development expenses consist primarily of labor, benefits and related employee expenses for personnel directly involved in product development activities; fees paid to professional service providers for monitoring and analyzing clinical trials; regulatory costs; costs of contract research and manufacturing of inventory used in testing and clinical trials. Product development expenses are expensed as incurred and reflect costs directly attributable to product candidates in development during the applicable period and to product candidates for which the Company has discontinued development. All indirect costs (such as salaries, benefits or other costs related to the Company’s accounting, legal, human resources, purchasing, information technology and other general corporate functions) associated with individual product candidates are included in general and administrative expenses.
Advertising	Advertising Advertising costs, which include promotional expenses and the cost of placebo samples, are expensed as incurred. Advertising expenses were $4.5 million, $3.8 million and $4.2 million for the years ended December 31, 2018, 2017 and 2016, respectively, and are included in selling, general and administrative expenses in the accompanying consolidated statements of operations.
Shipping and handling costs	Shipping and handling costs Shipping and handling costs, which include expenses from our wholesalers, are expensed as incurred. Shipping and handling costs were $0.02 million, $0.01 and $0.01 million for the years ended December 31, 2018, 2017 and 2016, respectively, and are included in selling, general and administrative expenses in the accompanying consolidated statements of operations.
Stock-based compensation	Stock-based compensation The Company has a stock-based compensation plan under which various types of equity-based awards are granted, including stock options, restricted stock units (RSUs) and performance-based RSUs. The fair value of stock option and RSUs, which are subject only to service conditions with graded vesting, are recognized as compensation expense, generally on a straight-line basis over the service period, net of estimated forfeitures. Forfeitures are recognized as they occur. The fair values of performance-based RSUs are recognized as compensation expense from the grant date to the end of the performance period. The Company uses the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (warrants and options). The grant date fair value of an RSU equals the closing price of our common stock on the trading day preceding the grant date. The fair value of each option and warrant is estimated on the date of grant using the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate. Expected volatility is based on historical volatility of the Company’s Common Stock and other factors estimated over the expected term of the options. The expected term of options granted is derived using the “simplified method” which computes expected term as the average of the sum of the vesting term plus the contract term. The risk-free rate is based on the U.S. Treasury yield. In applying the Black-Scholes options-pricing model, assumptions are as follows: 2018 2017 2016 Expected price volatility 60.34%-68.77% 68.76%-78.79% 62.65%-80.78% Risk-free interest rate 2.05%-3.00% 1.77%-2.05% 0.56%-1.70% Weighted average expected life in years 6 years 6 years 6 years Dividend yield — — —
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company measures the fair value of instruments in accordance with GAAP which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. GAAP also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. GAAP describes three levels of inputs that may be used to measure fair value: Level 1 – quoted prices in active markets for identical assets or liabilities Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)
Recent accounting pronouncements-adopted	Recent accounting pronouncements-adopted The SEC has released SEC Final Rule Release No. 33-10532 In the first quarter of 2018, the Company adopted Topic 606. Under the standard, revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration the entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The Company applied the five-step method outlined in the ASU to all revenue streams and elected the modified retrospective implementation method. The additional disclosures required by Topic 606 have been included in Note 2.
Recent accounting pronouncements-issued, not yet adopted	Recent accounting pronouncements-issued, not yet adopted In November 2018, the FASB issued ASU “Collaborative Arrangements (Topic 808) – Clarifying the Interaction between Topic 808 and Topic 606” (“ASU 2018-18”). 2018-18 make unit-of-account 2018-18 is ASU 2016-02, However, unlike current GAAP which requires only capital leases to be recognized on the balance sheet, the new ASU will require both types of leases (i.e., operating and finance leases) to be recognized on the balance sheet. The FASB lessee accounting model will continue to account for both types of leases. The finance lease will be accounted for in substantially the same manner as capital leases are accounted for under existing GAAP. The operating lease will be accounted for in a manner similar to operating leases under existing GAAP, except that lessees will recognize a lease liability and a right-of-use The Company will adopt and implement this standard on January 1, 2019, using the required modified-retrospective approach as of the effective date. The Company will elect the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allows us to carryforward the historical lease classification. The Company will make an accounting policy election to account for leases with an initial term of 12 months or less similar to existing guidance for operating leases today. The Company will recognize those lease payments in the Consolidated Statements of Operations on a straight-line basis over the lease term. The Company is substantially complete with its implementation to the new leasing standard and believes that the transition will not have a material impact on its consolidated balance sheet. As disclosed in Note 18 – Commitments and Contingencies, the Company has approximately $1.3 million in future minimum lease commitments as of the year ended December 31, 2018. Upon adoption, the Company’s lease liability will generally be based on the present value of such payments and the related right-of-use The Company has estimated the right-of-use

Nature of Business and Summar_3

Nature of Business and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Summary of Company's Customers Accounts Receivable	The following table lists the Company’s customers that individually comprise greater than 10% of total accounts receivable: December 31, Customers 2018 2017 Customer A 47 % 47 % Customer B 22 % 22 % Customer C 25 % 26 % Total 94 % 95 %
Summary of Inventories	Inventory is composed of the following at December 31: 2018 2017 Raw Materials & Supplies $ 645 $ 1,338 Work-in-process 2,093 3,135 Finished Goods 2,855 1,861 Finished Goods Reserve (187 ) (243 ) Total Inventories $ 5,406 $ 6,091
Intangible Assets with Finite Useful Lives, Amortized Over Estimated Useful Lives	Intangible assets with finite useful lives are amortized over the estimated useful lives as follows: Estimated Licenses 15 years BELBUCA license and distribution rights 10 years U.S. product rights 8-12 years EU product rights 7-11
Black Scholes Options-Pricing Model, Assumptions	In applying the Black-Scholes options-pricing model, assumptions are as follows: 2018 2017 2016 Expected price volatility 60.34%-68.77% 68.76%-78.79% 62.65%-80.78% Risk-free interest rate 2.05%-3.00% 1.77%-2.05% 0.56%-1.70% Weighted average expected life in years 6 years 6 years 6 years Dividend yield — — —

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	12 Months Ended
	Dec. 31, 2018
Revenue from Contract with Customer [Abstract]
Impact and cumilative effect of adoption of ASC 606 on condensed consolidated balance sheet, statement of operations and accounts receivables	The impact of adoption of Topic 606 on the Company’s consolidated balance sheet as of December 31, 2018 follows (in thousands): Consolidated Balance Sheet December 31, 2018 As reported Balances Effect of Accounts receivable, net $ 13,627 $ 13,462 $ 165 Accumulated deficit $ (351,288 ) $ (351,453 ) $ 165 The impact of adoption of Topic 606 on the Company’s consolidated statement of operations for the year ended December 31, 2018 follows (in thousands): Consolidated As Balances Effect of Product sales $ 51,410 $ 51,410 $ — Product royalty revenues 3,389 3,389 — Contract revenues 841 811 30 Total revenues $ 55,640 $ 55,610 $ 30 Net loss $ (33,867 ) $ (33,897 ) $ 30 The beginning and ending balances of the Company’s accounts receivables with customers from contracts during the periods presented is as follows (in thousands): Balance at Year Balance at Accounts receivable with customers $ 8,987 $ 4,640 $ 13,627

Accounts Payable and Accrued _2

Accounts Payable and Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2018
Payables and Accruals [Abstract]
Summary of Components of Accounts Payable and Accrued Liabilities	The following table represents the components of accounts payable and accrued liabilities as of December 31: 2018 2017 Accounts payable $ 3,166 $ 12,236 Accrued rebates 12,261 5,648 Accrued compensation and benefits 3,814 3,472 Accrued acquisition costs 318 2,311 Accrued returns 715 915 Accrued royalties 159 488 Accrued clinical trial costs 464 234 Accrued legal 70 216 Accrued other 572 629 Total accounts payable and accrued expenses $ 21,539 $ 26,149

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Summarized Category of Fixed Assets	Property and equipment, summarized by major category, consist of the following as of December 31: 2018 2017 Machinery & equipment $ 5,635 $ 5,428 Computer equipment & software 406 399 Office furniture & equipment 155 169 Leasehold improvements 43 44 Idle equipment 679 766 Total 6,918 6,806 Less accumulated depreciation (3,846 ) (3,028 ) Total property, plant & equipment, net $ 3,072 $ 3,778

Other Intangible Assets (Tables

Other Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2018
Text Block [Abstract]
Summary of Other Intangible Assets Net Consisting of Product Rights and Licenses	Other intangible assets, net, consisting of product rights and licenses are summarized as follows: December 31, 2018 Gross Carrying Accumulated Intangible Assets, Weighted average Product rights $ 6,050 $ (5,442 ) $ 608 1.08 BELBUCA license and distribution rights 45,000 (9,000 ) 36,000 7.65 Licenses 1,900 (1,805 ) 95 0.50 Total intangible assets $ 52,950 $ (16,247 ) $ 36,703 9.23 December 31, 2017 Gross Carrying Accumulated Intangible Assets, Weighted average Product rights $ 6,050 $ (4,881 ) $ 1,169 1.21 BELBUCA license and distribution rights 45,000 (4,500 ) 40,500 8.50 Licenses 1,900 (1,709 ) 191 0.54 Total intangible assets $ 52,950 $ (11,090 ) $ 41,860 10.25
Schedule Estimated Aggregate Future Amortization Expenses for Other Intangible Assets	Estimated aggregate future amortization expenses for other intangible assets for each of the next five years and thereafter are as follows: Years ending December 31, 2019 $ 5,157 2020 4,546 2021 4,500 2022 4,500 2023 4,500 Thereafter 13,500 $ 36,703

Business Combination and BELB_2

Business Combination and BELBUCA Acquisition (Tables) - BELBUCA [Member]	12 Months Ended
	Dec. 31, 2018
Summary of Asset Purchase Price and Estimated Values of Assets Acquired and Liabilities Assumed	The following table summarizes the consideration paid to acquire BELBUCA and the estimated values of assets acquired and liabilities assumed in the accompanying consolidated balance sheet based on their fair values on January 6, 2017 (the date of the Endo Closing): Asset purchase price: Deferred cash consideration to Endo $ 7,536 Total asset purchase price $ 7,536 Estimated fair value of assets acquired: BELBUCA product inventory and work-in $ 5,412 BELBUCA-related manufacturing equipment 432 License and distribution rights intangible assets 45,000 Deferred tax liability (15,972 ) Amount attributable to assets acquired $ 34,872 Bargain purchase gain $ (27,336 )
Summary of Proforma Impact of Acquisition	The following pro forma combined results of operations are provided for the year ended December 31, 2016, as though the BELBUCA acquisition had been completed as of January 1, 2016. These supplemental pro forma results of operations are provided for illustrative purposes only and do not purport to be indicative of the actual results that would have been achieved by the combined company for the period presented or that may be achieved by the combined company in the future. The pro forma results of operations do not include any cost savings or other synergies that resulted, or may result, from the BELBUCA acquisition or any estimated costs that will be incurred to integrate the BELBUCA product line, nor do they reflect the bargain purchase gain recognized. Future results may vary significantly from the results in this pro forma information because of future events and transactions, as well as other factors. (in thousands, except per share data) December 31, Revenue $ 25,010 Net loss $ (201,769 ) Pro forma net loss per common share Basic $ (3.76 ) Diluted $ (3.76 )

Notes Payable (Tables)

Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2018
Debt Disclosure [Abstract]
Future Maturities of the CRG Obligation	The following table represents future maturities of the CRG obligation as of December 31, 2018: 2019 $ — 2020 — 2021 30,892 2022 30,892 Total maturities $ 61,784 Unamortized discount and loan costs (10,132 ) Total notes payable obligation $ 51,652

Net Sales by Product (Tables)

Net Sales by Product (Tables)	12 Months Ended
	Dec. 31, 2018
Segment Reporting [Abstract]
Summary of Net Sales by Product	The following table presents net sales by product for each of the years ended December 31 (in thousands): Year ended December 31, 2018 2017 2016 BELBUCA $ 45,988 $ 26,980 $ — BUNAVAIL 5,422 7,942 8,266 Net product sales $ 51,410 $ 34,922 $ 8,266

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Reconciliation of Federal Statutory Income Tax Rate	Reconciliation of the Federal statutory income tax rate of 21% to the effective rate is as follows: 2018 2017 2016 Federal statutory income (benefit) tax rate 21.00 % (34.00 %) 34.00 % 2017 Tax Act, net deferred tax remeasurement — (626.73 ) — State taxes, net of federal benefit (0.11 ) (2.01 ) 2.88 Stock compensation (4.74 ) (5.18 ) (0.61 ) Permanent differences-other (1.33 ) (13.39 ) (1.00 ) North Carolina tax rate change — (32.75 ) — Research and development (“R&D”) credit — 5.54 0.98 Valuation release for bargain purchase gain — (302.23 ) — Other (2.07 ) (1.36 ) (0.47 ) Decrease (increase) in valuation allowance (12.65 ) 709.88 (35.78 ) 0.10 % (302.23 %) 0.00 %
Significant Components of Deferred Tax Assets and Liabilities	The tax effects of temporary differences and net operating losses that give rise to significant components of deferred tax assets and liabilities consist of the following: December 31, Deferred tax assets (liabilities) 2018 2017 Deferred revenue $ — $ — Basis difference in equipment (459 ) (587 ) Basis difference in intangibles (6,045 ) (8,288 ) Accrued liabilities and other 2,246 654 R&D credit 10,980 11,882 AMT credit — 79 Stock options 4,360 6,115 Net operating loss carry-forward 64,376 61,660 75,458 71,515 Less: valuation allowance (75,458 ) (71,515 ) $ — $ —

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2018
Federal Home Loan Banks [Abstract]
Summary of Restricted Stock Activity	Restricted stock activity during the year ended December 31, 2018 was as follows: Number of Weighted Outstanding at January 1, 2018 4,706,895 $ 5.20 Granted: Executive officers 1,183,750 2.25 Directors 469,261 2.59 Employees 381,250 2.28 Vested (1,863,731 ) 2.57 Forfeitures (591,398 ) 2.46 Conversions (2,119,925 ) 2.72 Outstanding at December 31, 2018 2,166,102 $ 2.59
Summary of Stock Option Activity	Stock option activity for the years ended December 31, 2018, 2017 and 2016 is as follows: Number of Weighted Average Aggregate Outstanding at January 1, 2016 3,397,529 $ 5.42 $ 3,124 Granted in 2016: Officers and Directors 95,000 $ 2.34 Others 558,373 3.12 Exercised (147,425 ) 2.01 Forfeitures (434,486 ) 13.17 Outstanding at December 31, 2016 3,468,991 $ 4.14 $ 0 Granted in 2017: Officers and Directors 83,658 $ 2.64 Others 873,017 1.96 Exercised (202,519 ) 2.17 Forfeitures (1,510,193 ) 5.13 Outstanding at December 31, 2017 2,712,954 $ 2.98 $ 1,190 Granted in 2018: Officers and Directors 1,249,817 $ 2.49 Others 1,299,360 2.60 Exercised (350,441 ) 2.00 Forfeitures (502,186 ) 3.48 Outstanding at December 31, 2018 4,406,004 $ 3.19 $ 4,172
Summary of Stock Options Outstanding	Options outstanding at December 31, 2018 are as follows: Range of Exercise Prices Number Weighted Average Weighted Average Aggregate $1.00 – 5.00 3,948,887 7.72 $ 2.70 $5.01 – 10.00 387,361 4.78 $ 5.91 $10.01 – 15.00 38,756 6.15 $ 13.09 $15.01 – 20.00 31,000 6.00 $ 16.20 4,406,004 $ 4,172
Summary of Stock Options Exercisable	Options exercisable at December 31, 2018 are as follows: Range of Exercise Prices Number Weighted Average Weighted Average Aggregate $1.00 – 5.00 1,196,693 4.07 $ 3.15 $5.01 – 10.00 375,722 4.71 $ 6.10 $10.01 – 15.00 38,756 6.15 $ 13.09 $15.01 – 20.00 31,000 5.80 $ 16.20 1,642,171 $ 653
Summary of Non-Vested Stock Options	Nonvested stock options as of December 31, 2018, and changes during the year then ended, are as follows: Nonvested Shares Shares Weighted Average Intrinsic Nonvested at January 1, 2018 885,484 Granted 2,549,177 Vested (209,500 ) Forfeited (461,328 ) Nonvested at December 31, 2018 2,763,833 $ 1.54 $ 5,979

Earnings per Common Share (Tabl

Earnings per Common Share (Tables)	12 Months Ended
	Dec. 31, 2018
Earnings Per Share [Abstract]
Reconciliation of Numerators and Denominators of Basic and Diluted Earnings Per Common Share Computations	The following is a reconciliation of the numerators and denominators of the basic and diluted earnings per common share computations for the years ended December 31, 2018, 2017 and 2016. December 31, 2018 2017 2016 Basic: Net (loss) income $ ( 33,867 ) $ 5,285 $ (67,138 ) Less deemed dividend related to beneficial conversion feature on Series B Preferred Stock (12,500 ) — — Net (loss) income attributable to common stockholders, basic $ (46,367 ) $ 5,285 $ (67,138 ) Weighted average common shares outstanding 63,165,063 55,355,802 53,679,134 Basic (loss) income per common share $ (0.73 ) $ 0.10 $ (1.25 ) December 31, 2018 2017 2016 Diluted: Effect of dilutive securities: Net (loss) income attributable to common stockholders, diluted $ (46,367 ) $ 5,285 $ (67,138 ) Weighted average common shares outstanding 63,165,063 55,355,802 53,679,134 Effect of dilutive options and warrants — 1,046,677 — Diluted weighted average common shares outstanding 63,165,063 56,402,479 53,679,134 Diluted (loss) income per common share $ (0.73 ) $ 0.09 $ (1.25 )
Schedule of Total Outstanding Options, RSUs and Warrants	The following is the total outstanding options, RSUs and warrants for the years ended December 31, 2018, 2017 and 2016, respectively. 2018 2017 2016 Options, RSUs, warrants and convertible preferred stock to purchase Common Stock 10,739,378 9,555,869 10,228,929

Commitments and contingencies (

Commitments and contingencies (Tables)	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Future Minimum Commitment on the Remaining Operating Lease	The future minimum commitment on the new operating lease at December 31, 2018 is as follows: Years ending December 31, 2019 $ 351 2020 360 2021 370 2022 219 $ 1,300

Selected Quarterly Results (U_2

Selected Quarterly Results (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2018
Quarterly Financial Information Disclosure [Abstract]
Selected Quarterly Results	The following table sets forth certain quarterly financial data for the periods indicated (in thousands, except per share data): Quarter Ended March 31, June 30, September 30, December 31, Revenue $ 11,281 $ 12,175 $ 14,156 $ 18,028 Gross profit 7,866 7,609 10,377 14,005 Loss from operations (8,123 ) (7,266 ) (3,811 ) (4,448 ) Net loss (10,709 ) (9,770 ) (18,880 ) (7,008 ) Basic loss per share (0.18 ) (0.16 ) (0.29 ) (0.13 ) Diluted loss per share (0.18 ) (016 ) (0.29 ) (0.13 ) Quarter Ended March 31, June 30, September 30, December 31, Revenue $ 29,478 $ 8,744 $ 11,253 $ 12,510 Gross profit 23,833 4,573 6,808 7,275 Income (loss) from operations 7,903 (12,987 ) (10,045 ) (14,291 ) Net income (loss) 48,325 (14,879 ) (11,951 ) (16,210 ) Basic income (loss) per share 0.89 (0.27 ) (0.21 ) (0.31 ) Diluted income (loss) per share 0.87 (0.27 ) (0.21 ) (0.30 ) Quarter Ended March 31, June 30, September 30, December 31, Revenue $ 3,040 $ 5,004 $ 3,571 $ 3,931 Gross profit 490 910 1,257 1,631 Loss from operations (17,942 ) (15,594 ) (15,199 ) (15,200 ) Net loss (18,733 ) (16,486 ) (15,977 ) (15,942 ) Basic loss per share (0.35 ) (0.31 ) (0.30 ) (0.29 ) Diluted loss per share (0.35 ) (0.31 ) (0.30 ) (0.29 )

Nature of Business and Summar_4

Nature of Business and Summary of Significant Accounting Policies - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2018USD ($)ManufacturerCustomer$ / shares	Dec. 31, 2017USD ($)$ / shares	Dec. 31, 2016USD ($)	Jan. 01, 2019USD ($)
Basis Of Presentation [Line Items]
Common Stock, par value | $ / shares	$ 0.001	$ 0.001
Preferred Stock, par value | $ / shares	$ 0.001
Number of contract manufacturers | Manufacturer	3
Percentage of amount due to vendors payable	6.30%	22.80%
Number of customers | Customer	3
FDIC insurance coverage	$ 250,000
Net deposit amount exceeding specified amount under FDIC	$ 43,600,000	$ 21,200,000
Discount for prompt payment	2.00%
Percentage of prompt payment discount, accrued	100.00%
Allowance for prompt payment of discount	$ 300,000	200,000
Allowance for Doubtful Accounts Receivable	0	0
Inventory obsolescence recorded	(56,000)	243,000
Impairment loss	78,000
Impairment charges recognized on finite lived intangibles assets	0	0	$ 0
Goodwill impairment charges	$ 0	0	0
Sales return maximum duration	18 months
Offered period for sales return prior to expiration	6 months
Offered period for sales return subsequent to expiration	12 months
Discount for prompt payment	2.00%
Advertising expenses	$ 4,500,000	3,800,000	4,200,000
Shipping and handling costs	15,783,000	$ 19,496,000	$ 11,258,000
Future minimum lease payments	$ 1,300,000
Subsequent Event [Member]
Basis Of Presentation [Line Items]
Right-of-use lease assets				$ 900,000
Lease liability				$ 1,000,000
Sales Revenue, Net [Member] | Customer Concentration Risk [Member]
Basis Of Presentation [Line Items]
Total annual sales percentage	92.00%	92.00%	91.00%
BUNAVAIL [Member]
Basis Of Presentation [Line Items]
Impairment loss	$ 0	$ 0
Shipping and Handling [Member]
Basis Of Presentation [Line Items]
Shipping and handling costs	$ 20,000	$ 10,000	$ 10,000
Minimum [Member]
Basis Of Presentation [Line Items]
Period of payments from customers	30 days
Estimated useful lives of equipment	3 years
Accrual to payment cycle period	1 month
Maximum [Member]
Basis Of Presentation [Line Items]
Period of payments from customers	37 days
Estimated useful lives of equipment	10 years
Accrual to payment cycle period	3 months

Nature of Business and Summar_5

Nature of Business and Summary of Significant Accounting Policies - Summary of Company's Customers Accounts Receivable (Detail) - Customer Concentration Risk [Member] - Accounts Receivable [Member]	Dec. 31, 2018	Dec. 31, 2017
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total Accounts Receivable	94.00%	95.00%
Customer A [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total Accounts Receivable	47.00%	47.00%
Customer B [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total Accounts Receivable	22.00%	22.00%
Customer C [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total Accounts Receivable	25.00%	26.00%

Nature of Business and Summar_6

Nature of Business and Summary of Significant Accounting Policies - Summary of Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Raw Materials & Supplies	$ 645	$ 1,338
Work-in-process	2,093	3,135
Finished Goods	2,855	1,861
Finished Goods Reserve	(187)	(243)
Total Inventories	$ 5,406	$ 6,091

Nature of Business and Summar_7

Nature of Business and Summary of Significant Accounting Policies - Intangible Assets with Finite Useful Lives, Amortized Over Estimated Useful Lives (Detail)	12 Months Ended
	Dec. 31, 2018
Licenses [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Lives	15 years
BELBUCA License and Distribution Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Lives	10 years
U.S. Product Rights [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Lives	8 years
U.S. Product Rights [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Lives	12 years
Eu Product Rights [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Lives	7 years
Eu Product Rights [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Lives	11 years

Nature of Business and Summar_8

Nature of Business and Summary of Significant Accounting Policies - Black Scholes Options-Pricing Model, Assumptions (Detail)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average expected life in years	6 years	6 years	6 years
Dividend yield	0.00%	0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected price volatility	60.34%	68.76%	62.65%
Risk-free interest rate	2.05%	1.77%	0.56%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected price volatility	68.77%	78.79%	80.78%
Risk-free interest rate	3.00%	2.05%	1.70%

Revenue from Contracts with C_3

Revenue from Contracts with Customers - Additional Information (Detail) - USD ($) $ in Thousands	Jan. 08, 2019	Jan. 01, 2018
New Accounting Pronouncement, Early Adoption [Line Items]
Cumulative impact to retained earnings of accounting change		$ 135
Subsequent Event [Member] | Purdue Agreement [Member]
New Accounting Pronouncement, Early Adoption [Line Items]
Reversal of revenue from contract	$ 200
License agreement effective date	Mar. 11, 2019

Revenue from Contracts with C_4

Revenue from Contracts with Customers - Impact of Adoption of Asc 606 on Company's Condensed Consolidated Balance Sheet (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Jan. 01, 2018	Dec. 31, 2017
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Accounts receivable, net	$ 13,627		$ 8,852
Accumulated deficit	(351,288)		$ (305,056)
Accounting Standards Update 2014-09 [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Accounts receivable, net		$ 8,987
Calculated under Revenue Guidance in Effect before Topic 606 [Member] | Accounting Standards Update 2014-09 [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Accounts receivable, net	13,462
Accumulated deficit	(351,453)
Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Accounting Standards Update 2014-09 [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Accounts receivable, net	165
Accumulated deficit	$ 165

Revenue from Contracts with C_5

Revenue from Contracts with Customers - Impact of Adoption of Asc 606 on Company's Condensed Consolidated Statement of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended												12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenues	$ 18,028	$ 14,156	$ 12,175	$ 11,281	$ 12,510	$ 11,253	$ 8,744	$ 29,478	$ 3,931	$ 3,571	$ 5,004	$ 3,040	$ 55,640	$ 61,985	$ 15,546
Net loss	$ (7,008)	$ (18,880)	$ (9,770)	$ (10,709)	$ (16,210)	$ (11,951)	$ (14,879)	$ 48,325	$ (15,942)	$ (15,977)	$ (16,486)	$ (18,733)	(33,867)	5,285	(67,138)
Product Sales [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenues													51,410	34,922	8,266
Product Royalty Revenues [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenues													3,389	5,070	3,646
Contract Revenues [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenues													841	$ 21,194	$ 2,500
Calculated under Revenue Guidance in Effect before Topic 606 [Member] | Accounting Standards Update 2014-09 [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenues													55,610
Net loss													(33,897)
Calculated under Revenue Guidance in Effect before Topic 606 [Member] | Product Sales [Member] | Accounting Standards Update 2014-09 [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenues													51,410
Calculated under Revenue Guidance in Effect before Topic 606 [Member] | Product Royalty Revenues [Member] | Accounting Standards Update 2014-09 [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenues													3,389
Calculated under Revenue Guidance in Effect before Topic 606 [Member] | Contract Revenues [Member] | Accounting Standards Update 2014-09 [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenues													811
Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Accounting Standards Update 2014-09 [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenues													30
Net loss													30
Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Contract Revenues [Member] | Accounting Standards Update 2014-09 [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenues													$ 30

Revenue from Contracts with C_6

Revenue from Contracts with Customers - Summary of Accounts Receivables with Customers from Contracts (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Jan. 01, 2018
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Accounts receivable with customers	$ 13,627	$ 8,852
Changes in accounts receivable with customers	$ 4,640	$ 5,884	$ 862
Accounting Standards Update 2014-09 [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Accounts receivable with customers				$ 8,987

Liquidity - Additional Informat

Liquidity - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Liquidity And Managements Plans [Abstract]
Cash	$ 43,822	$ 21,195	$ 32,019	$ 83,560
Net cash flows from operating activities	24,100
Stockholders' equity	$ 29,742	$ 8,877	$ (17,665)	$ 31,696

Accounts Payable and Accrued _3

Accounts Payable and Accrued Liabilities - Summary of Components of Accounts Payable and Accrued Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Payables and Accruals [Abstract]
Accounts payable	$ 3,166	$ 12,236
Accrued rebates	12,261	5,648
Accrued compensation and benefits	3,814	3,472
Accrued acquisition costs	318	2,311
Accrued returns	715	915
Accrued royalties	159	488
Accrued clinical trial costs	464	234
Accrued legal	70	216
Accrued other	572	629
Total accounts payable and accrued expenses	$ 21,539	$ 26,149

Accounts payable and Accrued _4

Accounts payable and Accrued Liabilities - Additional Information (Detail) - Vendor	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Accounts Payable And Accrued Expenses [Line Items]
Number of vendors	3	3
Accounts Payable [Member] | Supplier Concentration Risk [Member]
Accounts Payable And Accrued Expenses [Line Items]
Percentage of amount due to major vendors accounts payable	37.00%	39.00%

Property and Equipment - Summar

Property and Equipment - Summarized Category of Fixed Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Property, plant & equipment, gross	$ 6,918	$ 6,806
Less accumulated depreciation	(3,846)	(3,028)
Total property, plant & equipment, net	3,072	3,778
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant & equipment, gross	5,635	5,428
Computer Equipment and Software [Member]
Property, Plant and Equipment [Line Items]
Property, plant & equipment, gross	406	399
Office Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant & equipment, gross	155	169
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant & equipment, gross	43	44
Idle Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant & equipment, gross	$ 679	$ 766

Property and Equipment - Additi

Property and Equipment - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Depreciation other	$ 1	$ 0.7	$ 0.4

Other Intangible Assets - Summa

Other Intangible Assets - Summary of Other Intangible Assets Net Consisting of Product Rights and Licenses (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 52,950	$ 52,950
Accumulated Amortization	(16,247)	(11,090)
Intangible Assets, net	36,703	41,860
Product Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	6,050	6,050
Accumulated Amortization	(5,442)	(4,881)
Intangible Assets, net	608	1,169
License and Distribution Rights [Member] | BELBUCA [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	45,000	45,000
Accumulated Amortization	(9,000)	(4,500)
Intangible Assets, net	36,000	40,500
Licenses [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	1,900	1,900
Accumulated Amortization	(1,805)	(1,709)
Intangible Assets, net	$ 95	$ 191
Weighted average Useful Life	15 years
Weighted Average [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted average Useful Life	9 years 2 months 23 days	10 years 3 months
Weighted Average [Member] | Product Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted average Useful Life	1 year 29 days	1 year 2 months 15 days
Weighted Average [Member] | License and Distribution Rights [Member] | BELBUCA [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted average Useful Life	7 years 7 months 24 days	8 years 6 months
Weighted Average [Member] | Licenses [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted average Useful Life	6 months	6 months 14 days

Other Intangible Assets - Addit

Other Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense on other intangible assets	$ 5,157	$ 5,425	$ 971

Other Intangible Assets - Sched

Other Intangible Assets - Schedule Estimated Aggregate Future Amortization Expenses for Other Intangible Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
2019	$ 5,157
2020	4,546
2021	4,500
2022	4,500
2023	4,500
Thereafter	13,500
Intangible Assets, net	$ 36,703	$ 41,860

License and Development Agree_2

License and Development Agreements - Endo License and Development Agreement - Additional Information (Detail) - USD ($)	1 Months Ended	12 Months Ended
	Nov. 30, 2015	Dec. 31, 2018	Oct. 31, 2015
Revenue Recognition, Milestone Method [Line Items]
Potential milestone payment receivable upon regulatory approval			$ 50,000,000
Milestone payment upon regulatory approval deferred for future revenue recognition	$ 20,000,000
Patent extension starting period		2020
Patent extension ending period		2027
Royalty payment description		$50 million upon regulatory approval, earned in October 2015 and received in November 2015. Of the $50 million received in November 2015, $20 million related to a patent extension and was recorded as deferred revenue because all or a portion of such $20 million was contingently refundable to Endo if a third party generic product was introduced in the U.S. during the patent extension period from 2020 to 2027. However, due to the Company and Endo entering into a Termination Agreement on December 7, 2016 which terminated the BELBUCA license to Endo effective January 6, 2017, the deferred $20 million was recognized as revenue in January 2017. (See note 8, Business Combinations and BELBUCA Acquisition).
Endo Agreement [Member]
Revenue Recognition, Milestone Method [Line Items]
Deferred revenue refund payment		$ 20
Termination agreement date		Dec. 7, 2016
License termination effective date		Jan. 6, 2017

License and Development Agree_3

License and Development Agreements - Collegium License and Development Agreement - Additional Information (Detail) - Collegium License and Development Agreement [Member] $ in Millions	1 Months Ended
	Jun. 30, 2016USD ($)
Revenue Recognition, Milestone Method [Line Items]
Non-refundable payment received	$ 2.5
Execution term of license agreement	30 days

Business Combination and BELB_3

Business Combination and BELBUCA Acquisition - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Jan. 06, 2017
Business Acquisition [Line Items]
Income tax benefit	$ (13)	$ 15,972
BELBUCA [Member]
Business Acquisition [Line Items]
Useful life of equipment	7 years
Deferred tax liability			$ (15,972)
Income tax benefit		$ 16,000
BELBUCA [Member] | License and Distribution Rights [Member]
Business Acquisition [Line Items]
Amortization of intangible asset	10 years
Endo Agreement [Member]
Business Acquisition [Line Items]
Termination agreement date	Dec. 7, 2016
License termination effective date	Jan. 6, 2017
Potential milestone payments on intellectual property rights	$ 5,000
Term of Endo Agreement	2 years
Contract termination claims, description	In addition to the Purchase Price, pursuant to the terms of the Termination Agreement, the Company also paid to Endo a fee in the amount of $5 million in consideration for (i) Endo's agreement not to compete for a period of two years from the closing date of the termination agreement and (ii) Endo's waiver of its right to sell product for twelve months following the closing of the termination agreement.

Business Combination and BELB_4

Business Combination and BELBUCA Acquisition - Summary of Asset Purchase Price and Estimated Values of Assets Acquired and Liabilities Assumed (Detail) - USD ($) $ in Thousands	Jan. 06, 2017	Dec. 31, 2018	Dec. 31, 2017
Asset purchase price:
Deferred cash consideration to Endo		$ 1,951	$ 5,853
Estimated fair value of assets acquired:
Bargain purchase gain			$ (27,336)
BELBUCA [Member]
Asset purchase price:
Deferred cash consideration to Endo	$ 7,536
Total asset purchase price	7,536
Estimated fair value of assets acquired:
BELBUCA product inventory and work-in process	5,412
BELBUCA-related manufacturing equipment	432
License and distribution rights intangible assets	45,000
Deferred tax liability	(15,972)
Amount attributable to assets acquired	34,872
Bargain purchase gain	$ (27,336)

Business Combination and BELB_5

Business Combination and BELBUCA Acquisition - Summary of Proforma Impact of Acquisition (Detail) - BELBUCA [Member] $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016USD ($)$ / shares
Business Acquisition [Line Items]
Revenue | $	$ 25,010
Net loss | $	$ (201,769)
Pro forma net loss per common share
Basic | $ / shares	$ (3.76)
Diluted | $ / shares	$ (3.76)

Other License Agreements and _2

Other License Agreements and Acquired Product Rights - Additional Information (Detail) $ in Millions	Oct. 07, 2010USD ($)	Jan. 08, 2019	Dec. 31, 2018CAD ($)	Mar. 31, 2018CAD ($)	Oct. 31, 2017CAD ($)	Aug. 31, 2017CAD ($)	Sep. 30, 2013USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Jul. 12, 2017CAD ($)
Subsequent Event [Member] | Purdue Pharma [Member] | BELBUCA [Member]
Other License Agreements And Acquired Product Rights [Line Items]
License agreement effective date		Mar. 11, 2019
Collaborative Arrangement, Product [Member] | Purdue Pharma [Member] | BELBUCA [Member]
Other License Agreements And Acquired Product Rights [Line Items]
Upfront and potential milestones payable											$ 1,500,000
Milestone based payments received			$ 1,000,000	$ 1,000,000	$ 1,000,000	$ 500,000
Collaborative Arrangement, Product [Member] | Purdue Pharma [Member] | BELBUCA [Member] | Maximum [Member]
Other License Agreements And Acquired Product Rights [Line Items]
Upfront and potential milestones payable											$ 4,500,000
TTY License and Supply Agreement [Member]
Other License Agreements And Acquired Product Rights [Line Items]
Upfront payment	$ 0.3
Term of the agreement								15 years
Milestone payment received							$ 0.3	$ 1.5	$ 1.2	$ 0.9
TTY License and Supply Agreement [Member] | Maximum [Member]
Other License Agreements And Acquired Product Rights [Line Items]
Milestone payments	$ 1.3

Notes Payable - Additional Info

Notes Payable - Additional Information (Detail)	May 16, 2018USD ($)	Dec. 26, 2017USD ($)$ / sharesshares	Feb. 21, 2017USD ($)Warrant$ / sharesshares	Dec. 31, 2018$ / sharesshares	Dec. 31, 2017USD ($)
Debt Instrument [Line Items]
Remainder of borrowings			$ 13,700,000
Interest period of loan agreement	1 year
Minimum [Member]
Debt Instrument [Line Items]
Market capitalization	$ 200,000,000
CRG [Member] | Line of Credit [Member]
Debt Instrument [Line Items]
License termination effective date				Feb. 21, 2017
Number of warrants to purchase common stock | shares		349,452	1,701,583
Exercise price of warrants to purchase common stock | $ / shares		$ 3.42	$ 2.38
Borrowings outstanding			$ 45,000,000
Additional borrowing capacity upon milestone achievement			15,000,000
Second draw borrowing capacity upon milestone achievement			$ 5,000,000
Loan agreement term			6 years
Loan agreement interest only term			3 years
Interest on borrowings			12.50%
Interest on borrowings, interest only period percentage			3.50%
Final payment fee rate			9.00%
Prepayment period of outstanding principal and accrued unpaid interest			5 years
Prepayment fee after			$ 0
Additional interest rate			4.00%
Number of warrants | Warrant			5
CRG [Member] | Tranche Two [Member] | Line of Credit [Member]
Debt Instrument [Line Items]
Net proceeds in aggregate amount		$ 15,000,000
MidCap Financial Trust [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Net proceeds in aggregate amount			$ 29,400,000
Number of warrants to purchase common stock | shares				84,986
Exercise price of warrants to purchase common stock | $ / shares				$ 3.53
Class Of Warrant Or Rights Date From Which Warrants Or Rights Expired				2021-05
MidCap Financial Trust [Member] | Secured Debt [Member] | Interest Expense [Member]
Debt Instrument [Line Items]
Deferred loan costs expensed					$ 700,000

Notes Payable - Future Maturiti

Notes Payable - Future Maturities of the CRG Obligation (Detail) - CRG [Member] - Line of Credit [Member] $ in Thousands	Dec. 31, 2018USD ($)
Debt Instrument [Line Items]
2019	$ 0
2020	0
2021	30,892
2022	30,892
Total maturities	61,784
Unamortized discount and loan costs	(10,132)
Total notes payable obligation	$ 51,652

Net Sales by Product - Addition

Net Sales by Product - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2018Segment
Segment Reporting [Abstract]
Number of reportable segment	1

Net Sales by Product - Summary

Net Sales by Product - Summary of Net Sales by Product (Detail) - USD ($) $ in Thousands	3 Months Ended												12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Sales Information [Line Items]
Net product sales	$ 18,028	$ 14,156	$ 12,175	$ 11,281	$ 12,510	$ 11,253	$ 8,744	$ 29,478	$ 3,931	$ 3,571	$ 5,004	$ 3,040	$ 55,640	$ 61,985	$ 15,546
BELBUCA [Member]
Sales Information [Line Items]
Net product sales													45,988	26,980
BUNAVAIL [Member]
Sales Information [Line Items]
Net product sales													5,422	7,942	8,266
Product Sales [Member]
Sales Information [Line Items]
Net product sales													$ 51,410	$ 34,922	$ 8,266

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	Dec. 31, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Tax [Line Items]
Statutory income tax rate		21.00%	(34.00%)	34.00%
Tax Cuts and Jobs Act, Accounting Complete		true
Tax Cuts and Jobs Act, Refundable tax credit percentage		50.00%
State income tax expense		$ 50,000
Minimum percentage of likelihood of realization of deferred tax assets		50.00%
Uncertain income tax positions	$ 0	$ 0
Domestic Country [Member]
Income Tax [Line Items]
Operating Loss carry forward	279,000,000	279,000,000
Net operating loss used to offset taxable income	1,500,000	1,500,000
Domestic Country [Member] | Indefinite [Member]
Income Tax [Line Items]
Operating Loss carry forward	$ 3,280,000	3,280,000
Domestic Country [Member] | Minimum [Member]
Income Tax [Line Items]
Operating loss carry forward expiration term	Dec. 31, 2024
Domestic Country [Member] | Maximum [Member]
Income Tax [Line Items]
Operating loss carry forward expiration term	Dec. 31, 2037
State and Local Jurisdiction [Member]
Income Tax [Line Items]
Operating Loss carry forward	$ 264,000,000	$ 264,000,000
Operating loss carry forward expiration term		Dec. 31, 2030

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Federal Statutory Income Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Taxes [Line Items]
Federal statutory income (benefit) tax rate	21.00%	(34.00%)	34.00%
2017 Tax Act, net deferred tax remeasurement		(626.73%)
State taxes, net of federal benefit	(0.11%)	(2.01%)	2.88%
Stock compensation	(4.74%)	(5.18%)	(0.61%)
Permanent differences-other	(1.33%)	(13.39%)	(1.00%)
Research and development ("R&D") credit		5.54%	0.98%
Valuation release for bargain purchase gain		(302.23%)
Other	(2.07%)	(1.36%)	(0.47%)
Decrease (increase) in valuation allowance	(12.65%)	709.88%	(35.78%)
Federal statutory income tax rate, Total	0.10%	(302.23%)	0.00%
North Carolina [Member]
Income Taxes [Line Items]
North Carolina tax rate change		(32.75%)

Income Taxes - Significant Comp

Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Deferred revenue	$ 0	$ 0
Basis difference in equipment	(459)	(587)
Basis difference in intangibles	(6,045)	(8,288)
Accrued liabilities and other	2,246	654
R&D credit	10,980	11,882
AMT credit		79
Stock options	4,360	6,115
Net operating loss carry-forward	64,376	61,660
Gross, Deferred Tax Assets	75,458	71,515
Less: valuation allowance	(75,458)	(71,515)
Net of Valuation Allowance	$ 0	$ 0

Stockholders' Equity - Addition

Stockholders' Equity - Additional information (Detail) - USD ($)	Nov. 09, 2018	Aug. 23, 2017	Dec. 31, 2018	May 31, 2018	Mar. 31, 2018	Jul. 11, 2011	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2012	Aug. 02, 2018	Aug. 01, 2018	Feb. 28, 2017	Dec. 03, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common shares, authorized			125,000,000				125,000,000	75,000,000				125,000,000	75,000,000
Preferred Stock, par value			$ 0.001				$ 0.001
Authorized shares of preferred stock			5,000,000				5,000,000
Adjustments to additional paid in capital dividends in excess of retained earnings							$ 12,500,000
Number of RSUs vested							209,500
Company employees, directors and affiliates stock option exercised							350,441	202,519	147,425
Proceeds from common stock							$ 670,000	$ 439,000	$ 297,000
Weighted average grant date fair value of options granted							$ 1.57	$ 1.46	$ 1.75
Number of options granted in period with exercise price below market price							0	0	0
Unrecognized compensation cost related to non-vested share-based compensation awards granted			$ 6,900,000				$ 6,900,000
Unrecognized compensation cost related to non-vested share-based compensation awards granted year							4 years
Options outstanding			4,406,004				4,406,004	2,712,954	3,468,991	3,397,529
Fair value of warrants								$ 6,000,000
2011 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increase in shares of common stock authorized			7,100,000				7,100,000
2011 Equity Incentive Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common shares, authorized			11,050,000				11,050,000
2011 Equity Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common shares, authorized			18,150,000				18,150,000
Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock options outstanding and exercisable						523,854
Term that options may be awarded						10 years
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of equity instruments awarded in period							2,034,261
Fair market value of RSUs granted							$ 4,700,000
Vesting period of options							3 years
Restricted Stock Units (RSUs) [Member] | LTIP [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of equity instruments awarded in period							0	0		35,000
Restricted stock units ("RSUs") issued to directors and key employees							1,078,000				978,000
Restricted stock units reserved for future officers										100,000
RSU's Vested per performance criteria during period							8 years
Number of RSUs vested							31,036	9,958	13,347
Series B Non-Voting Convertible Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Preferred Stock, par value			$ 0.001	$ 0.001			$ 0.001	$ 0.001
Authorized shares of preferred stock			5,000,000				5,000,000	5,000,000
Series B preferred shares outstanding			3,100				3,100	0
Sale and issue of preferred stock				5,000
Purchase price of preferred stock				$ 10,000
Adjustments to additional paid in capital dividends in excess of retained earnings							$ 12,500,000
Series B Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Series B preferred shares outstanding			3,100				3,100
Conversion price				$ 1.80
Series B conversion to Common Stock				27,777,778			(1,900)
Series A Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized shares of preferred stock			2,285,700				2,285,700
Liquidation, dissolution or winding up, holders of the Series A Preferred per share payment															$ 0.001
Series B preferred shares outstanding			2,093,155				2,093,155
Series A Preferred stock converted							0	0	0
Employees and Directors Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Company employees, directors and affiliates stock option exercised							400,000	200,000	100,000
Proceeds from common stock							$ 700,000	$ 400,000	$ 300,000
Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding			84,986				84,986
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Company's securities for shelf registration	$ 150,000,000
Series B conversion to Common Stock							10,555,556
Company employees, directors and affiliates stock option exercised							350,441	202,519	147,426
MidCap Financial Trust [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock									84,986
Exercise price of warrants									$ 3.53
Fair value of warrants									$ 50,000
CRG [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock								349,451						1,701,583
Exercise price of warrants								$ 3.42						$ 2.38
Fair value of warrants								$ 1,500,000						$ 4,500,000
CRG [Member] | Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding			2,051,034				2,051,034
Dr.Mark Sirgo
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period shares upon employee retirement		795,730
Issuance of common stock upon employee retirement			285,305				285,305
Dr. Niraj Vasisht
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period shares upon employee retirement			65,000		309,162
Issuance of common stock upon employee retirement			198,129				198,129
Directors and Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of equity instruments awarded in period							2,549,177
Fair market value of shares granted							$ 3,900,000
Term of options granted period							10 years
Directors and Employees [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
RSU's Vested per performance criteria during period							1 year
Directors and Employees [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
RSU's Vested per performance criteria during period							3 years

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Restricted Stock Activity (Detail) - Restricted Stock Units (RSUs) [Member]	12 Months Ended
	Dec. 31, 2018$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of restricted shares, Outstanding at beginning of period	4,706,895
Number of Shares, Granted	2,034,261
Number of restricted shares, Vested	(1,863,731)
Number of restricted shares, Forfeitures	(591,398)
Number of restricted shares, Conversions	(2,119,925)
Number of restricted shares, Outstanding at end of period	2,166,102
Weighted average fair market value per RSU, Outstanding at beginning of period | $ / shares	$ 5.20
Weighted average fair market value per RSU, Vested | $ / shares	2.57
Weighted average fair market value per RSU, Forfeitures | $ / shares	2.46
Weighted average fair market value per RSU, Conversions | $ / shares	2.72
Weighted average fair market value per RSU, Outstanding at end of period | $ / shares	$ 2.59
Executive Officers [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Granted	1,183,750
Weighted average fair market value per RSU, Granted | $ / shares	$ 2.25
Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Granted	469,261
Weighted average fair market value per RSU, Granted | $ / shares	$ 2.59
Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Granted	381,250
Weighted average fair market value per RSU, Granted | $ / shares	$ 2.28

Stockholders' Equity - Summar_2

Stockholders' Equity - Summary of Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding at beginning of period	2,712,954	3,468,991	3,397,529
Number of Shares, Granted	2,549,177
Number of Shares, Exercised	(350,441)	(202,519)	(147,425)
Number of Shares, Forfeitures	(502,186)	(1,510,193)	(434,486)
Number of Shares, Outstanding at end of period	4,406,004	2,712,954	3,468,991
Weighted Average Exercise Price Per Share, Outstanding at beginning of period	$ 2.98	$ 4.14	$ 5.42
Weighted average Exercise Price Per Share, Exercised	2	2.17	2.01
Weighted Average Exercise Price Per Share, Forfeitures	3.48	5.13	13.17
Weighted Average Exercise Price Per Share, Outstanding at end of period	$ 3.19	$ 2.98	$ 4.14
Aggregate Intrinsic Value, Outstanding at beginning of period	$ 1,190	$ 0	$ 3,124
Aggregate Intrinsic Value, Granted	$ 0	$ 0	$ 0
Aggregate Intrinsic Value, Outstanding at end of period	$ 4,172	$ 1,190	$ 0
Officers and Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Granted	1,249,817	83,658	95,000
Weighted Average Exercise Price Per Share, Granted	$ 2.49	$ 2.64	$ 2.34
Others [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Granted	1,299,360	873,017	558,373
Weighted Average Exercise Price Per Share, Granted	$ 2.60	$ 1.96	$ 3.12

Stockholders' Equity - Summar_3

Stockholders' Equity - Summary of Stock Options Outstanding (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding	4,406,004
Aggregate Intrinsic Value	$ 4,172	$ 1,190	$ 0	$ 3,124
$1.00 - 5.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, minimum	$ 1
Range of Exercise Prices, maximum	$ 5
Number Outstanding	3,948,887
Weighted Average Remaining Contractual Life (Years)	7 years 8 months 19 days
Weighted Average Exercise Price	$ 2.70
$5.01 - 10.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, minimum	5.01
Range of Exercise Prices, maximum	$ 10
Number Outstanding	387,361
Weighted Average Remaining Contractual Life (Years)	4 years 9 months 10 days
Weighted Average Exercise Price	$ 5.91
$ 10.01 - 15.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, minimum	10.01
Range of Exercise Prices, maximum	$ 15
Number Outstanding	38,756
Weighted Average Remaining Contractual Life (Years)	6 years 1 month 24 days
Weighted Average Exercise Price	$ 13.09
$15.01 - 20.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, minimum	15.01
Range of Exercise Prices, maximum	$ 20
Number Outstanding	31,000
Weighted Average Remaining Contractual Life (Years)	6 years
Weighted Average Exercise Price	$ 16.20

Stockholders' Equity - Summar_4

Stockholders' Equity - Summary of Stock Options Exercisable (Detail) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2018USD ($)$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Exercisable | shares	1,642,171
Aggregate Intrinsic Value | $	$ 653
$1.00 - 5.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, minimum	$ 1
Range of Exercise Prices, maximum	$ 5
Number Exercisable | shares	1,196,693
Weighted Average Remaining Contractual Life (Years)	4 years 25 days
Weighted Average Exercise Price	$ 3.15
$5.01 - 10.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, minimum	5.01
Range of Exercise Prices, maximum	$ 10
Number Exercisable | shares	375,722
Weighted Average Remaining Contractual Life (Years)	4 years 8 months 15 days
Weighted Average Exercise Price	$ 6.10
$ 10.01 - 15.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, minimum	10.01
Range of Exercise Prices, maximum	$ 15
Number Exercisable | shares	38,756
Weighted Average Remaining Contractual Life (Years)	6 years 1 month 24 days
Weighted Average Exercise Price	$ 13.09
$15.01 - 20.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, minimum	15.01
Range of Exercise Prices, maximum	$ 20
Number Exercisable | shares	31,000
Weighted Average Remaining Contractual Life (Years)	5 years 9 months 18 days
Weighted Average Exercise Price	$ 16.20

Stockholders' Equity - Summar_5

Stockholders' Equity - Summary of Non-Vested Stock Options (Detail) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2018USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]
Nonvested at beginning of period	885,484
Nonvested, Shares, Granted	2,549,177
Nonvested, Shares, Vested	(209,500)
Nonvested, Shares, Forfeited	(461,328)
Nonvested at end of period	2,763,833
Weighted Average Grant Date Fair Value, Nonvested at December 31, 2018 | $ / shares	$ 1.54
Nonvested at December 31, 2018 ,Aggregate Intrinsic Value | $	$ 5,979

Earnings per Common Share - Rec

Earnings per Common Share - Reconciliation of Numerators and Denominators of Basic and Diluted Earnings Per Common Share Computations (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended												12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Basic:
Net (loss) income	$ (7,008)	$ (18,880)	$ (9,770)	$ (10,709)	$ (16,210)	$ (11,951)	$ (14,879)	$ 48,325	$ (15,942)	$ (15,977)	$ (16,486)	$ (18,733)	$ (33,867)	$ 5,285	$ (67,138)
Less deemed dividend related to beneficial conversion feature on Series B Preferred Stock													(12,500)
Net (loss) income attributable to common stockholders, basic													$ (46,367)	$ 5,285	$ (67,138)
Weighted average common shares outstanding													63,165,063	55,355,802	53,679,134
Basic (loss) income per common share	$ (0.13)	$ (0.29)	$ (0.16)	$ (0.18)	$ (0.31)	$ (0.21)	$ (0.27)	$ 0.89	$ (0.29)	$ (0.30)	$ (0.31)	$ (0.35)	$ (0.73)	$ 0.10	$ (1.25)
Effect of dilutive securities:
Net (loss) income attributable to common stockholders, diluted													$ (46,367)	$ 5,285	$ (67,138)
Weighted average common shares outstanding													63,165,063	55,355,802	53,679,134
Effect of dilutive options and warrants														1,046,677
Diluted weighted average common shares outstanding													63,165,063	56,402,479	53,679,134
Diluted (loss) income per common share	$ (0.13)	$ (0.29)	$ (16)	$ (0.18)	$ (0.30)	$ (0.21)	$ (0.27)	$ 0.87	$ (0.29)	$ (0.30)	$ (0.31)	$ (0.35)	$ (0.73)	$ 0.09	$ (1.25)

Earnings per Common Share - Add

Earnings per Common Share - Additional Information (Detail) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Earnings Per Share [Abstract]
Securities excluded from computation of diluted earnings per share	28,424,998	6,531,346	10,228,929

Earnings per Common Share - Sch

Earnings per Common Share - Schedule of Total Outstanding Options, RSUs and Warrants (Detail) - shares	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Earnings Per Share [Abstract]
Options, RSUs, warrants and convertible preferred stock to purchase Common Stock	10,739,378	9,555,869	10,228,929

Retirement Plan - Additional In

Retirement Plan - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Employers' sponsors contribution retirement plan	90.00%
Contribution to retirement plan, percentage of employee contribution	100.00%
Employers' sponsors contribution retirement plan amount	$ 0.8	$ 0.5	$ 0.4
Maximum [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Percentage of employee contribution to retirement plan	5.00%

Separation Agreement - Addition

Separation Agreement - Additional Information (Detail) $ in Thousands	Jan. 23, 2019USD ($)
Separation Agreement [Member] | Chief Financial Officer [Member] | Subsequent Event [Member]
Defined Benefit Plan Disclosure [Line Items]
Cash payment paid	$ 360

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Contingencies And Commitments [Line Items]
Lease expense		$ 300,000	$ 300,000	$ 300,000
Lease term		89 months
CDC [Member]
Contingencies And Commitments [Line Items]
Royalties received			$ 20,000
Granted royalty on sales of the next BEMA product			1.00%
Net sales of next BEMA Product			$ 7,500,000
Minimum [Member] | CDC [Member]
Contingencies And Commitments [Line Items]
Royalties received		$ 375,000
Opioid PMR Consortium [Member]
Contingencies And Commitments [Line Items]
Participation expense	$ 4,300,000

Commitments and Contingencies_2

Commitments and Contingencies - Future Minimum Commitment on the Remaining Operating Lease (Detail) $ in Thousands	Dec. 31, 2018USD ($)
Commitments and Contingencies Disclosure [Abstract]
2019	$ 351
2020	360
2021	370
2022	219
Total operating lease	$ 1,300

Selected Quarterly Results (U_3

Selected Quarterly Results (Unaudited) - Selected Quarterly Results (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended												12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Selected Quarterly Financial Information [Abstract]
Revenue	$ 18,028	$ 14,156	$ 12,175	$ 11,281	$ 12,510	$ 11,253	$ 8,744	$ 29,478	$ 3,931	$ 3,571	$ 5,004	$ 3,040	$ 55,640	$ 61,985	$ 15,546
Gross profit	14,005	10,377	7,609	7,866	7,275	6,808	4,573	23,833	1,631	1,257	910	490
Income (loss) from operations	(4,448)	(3,811)	(7,266)	(8,123)	(14,291)	(10,045)	(12,987)	7,903	(15,200)	(15,199)	(15,594)	(17,942)	(23,648)	(29,420)	(63,935)
Net income (loss)	$ (7,008)	$ (18,880)	$ (9,770)	$ (10,709)	$ (16,210)	$ (11,951)	$ (14,879)	$ 48,325	$ (15,942)	$ (15,977)	$ (16,486)	$ (18,733)	$ (33,867)	$ 5,285	$ (67,138)
Basic income (loss) per share	$ (0.13)	$ (0.29)	$ (0.16)	$ (0.18)	$ (0.31)	$ (0.21)	$ (0.27)	$ 0.89	$ (0.29)	$ (0.30)	$ (0.31)	$ (0.35)	$ (0.73)	$ 0.10	$ (1.25)
Diluted income (loss) per share	$ (0.13)	$ (0.29)	$ (16)	$ (0.18)	$ (0.30)	$ (0.21)	$ (0.27)	$ 0.87	$ (0.29)	$ (0.30)	$ (0.31)	$ (0.35)	$ (0.73)	$ 0.09	$ (1.25)

Schedule II - Valuation and Qua

Schedule II - Valuation and Qualifying Accounts and Reserves (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Valuation Allowance for Deferred Tax Assets [Member]
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at beginning of the period	$ 71,515	$ 109,030	$ 84,960
Charged to income	3,943	(37,515)	24,070
Balance at end of the period	75,458	71,515	109,030
Allowance for Rebates [Member]
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at beginning of the period	5,648	3,842	4,470
Charged to income	37,071	17,236	(1,204)
Charged to other accounts	813	(132)	11,501
Deductions	(31,270)	(15,298)	(10,925)
Balance at end of the period	12,261	5,648	3,842
Allowance for Price Adjustments and Chargebacks [Member]
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at beginning of the period	3,925	602	383
Charged to income	13,033	6,738	36
Charged to other accounts		(3)	1,711
Deductions	(12,940)	(3,412)	(1,528)
Balance at end of the period	4,018	3,925	$ 602
Allowance for inventory obsolescence [Member]
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at beginning of the period	243
Charged to income	(56)	243
Balance at end of the period	$ 187	$ 243